

CURRICULUM VITAE

Napoleone Ferrara, M.D.

University of California San Diego Medical Center
3855 Health Sciences Drive, Room 3310, Mail Code 0819
La Jolla, CA 92093
(858) 822-6822 (office)
(858) 534-2157 (fax)
(858) 736-6089 (cell)
nferrara@ucsd.edu
ferraranapoleone@gmail.com
ORCID: <https://orcid.org/0000-0002-7029-6375>

Date and place of birth

July 26, 1956, Catania, Italy

Citizenship

USA and Italy

Home address

550 Front St. # 1103,
San Diego, CA 92101

Positions held

Hildyard Endowed Chair in Eye Disease (July 2020-)
Distinguished Professor of Pathology,
Distinguished Adjunct Professor of Ophthalmology
Distinguished Adjunct Professor of Pharmacology
University of California, San Diego
(January 2013-)
<https://profiles.ucsd.edu/napoleone.ferrara>

Genentech Fellow

Genentech, Inc.
(May 2002-December 2012)

Staff Scientist

Genentech, Inc.
(February 1997-April 2002)

Senior Scientist

Genentech, Inc.
(February 1993-January 1997)

Scientist

Genentech, Inc.

(June 1988-January 1993)

Research Fellow

Cancer Research Institute

University of California, San Francisco.

San Francisco, CA

(July 1986-June 1988)

Intern

Dept. of Obstetrics and Gynecology

Oregon Health Sciences University

Portland, OR

(July 1985-June 1986)

Research Fellow

Reproductive Endocrinology Center,

Dept. of Obstetrics, Gynecology and Reproductive Sciences

Univ. of California, San Francisco.

San Francisco, CA

(January 1983-June 1985)

Education

University of Catania Medical School,

Catania, Italy

(November 1974-February 1981)

M.D. (cum laude) April 3, 1981

Liceo Classico Mario Cutelli

Catania, Italy

(October 1969-July 1974)

Maturita' Classica, July 1974

Research interests and major accomplishments

The main research interests of my laboratory are the biology of angiogenesis and the identification of its regulators. In 1989 we were the first to report the isolation and cDNA cloning of vascular endothelial growth factor (VEGF) and proposed that this molecule plays a unique role in the regulation of angiogenesis. My laboratory focused on the investigation of the molecular and biological properties of VEGF. In 1993 we reported that inhibition of VEGF by specific monoclonal antibodies results in suppression of growth of a variety of tumors in vivo. These findings represented the first direct evidence that inhibition of angiogenesis can block tumor growth. These studies led to the development of a humanized anti-VEGF monoclonal antibody (Bevacizumab; Avastin^R) as a cancer therapy. Bevacizumab has been approved by the USA FDA and worldwide for the treatment of multiple malignancies. Also, we discovered that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. These studies resulted in the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis^R),

which has been approved as therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the course of these blinding disorders. Recent studies indicate a substantial reduction in the incidence rate of legal blindness due to AMD following the availability of anti-VEGF therapy. We are presently investigating mechanisms of tumor and ocular angiogenesis alternative to VEGF and novel approaches to regenerate the vascular endothelium.

Honors/Awards

Selected awards

1. American-Italian Cancer Foundation Prize for Scientific Excellence in Medicine. New York, NY, Nov. 15, 2004.
2. American Association for Cancer Research (AACR) Bruce F. Cain Memorial Award. Anaheim, CA, April 19, 2005.
3. Lefoulon-Delalande-Institut-de-France Scientific Prize. Paris, France, June 15, 2005.
4. Passano Foundation Award. Baltimore, MD, April 25, 2006.
5. Elected to the National Academy of Sciences, USA. April 25, 2006.
6. General Motors Cancer Research Award. Bethesda, MD, June 13, 2006.
7. American Society for Clinical Oncology (ASCO) Science of Oncology Award. Chicago, IL, June 4, 2007.
8. Pezcoller Foundation-AACR International Award. Denver, CO, April 19, 2009.
9. Lasker-DeBakey Clinical Medical Research Award. New York, NY, October 1, 2010.
10. Dr. Paul Janssen Award for Biomedical Research. Beerse, Belgium, Sept. 15, 2011.
11. Breakthrough Prize in Life Sciences. February 20, 2013.
12. Champalimaud Vision Award. Lisbon, Portugal, Sept. 10, 2014.
13. Canada Gairdner International Award. Toronto, Canada, Oct. 30, 2014.
14. Elected to the National Academy of Medicine, USA. Oct. 1, 2015.
15. Keio Medical Science Prize. Tokyo, Japan, Nov. 9, 2023.
16. Prince Mahidol Award in Medicine. Bangkok, Thailand, Jan. 24, 2024.
17. Elected to "Accademia Nazionale dei Lincei". Rome, Italy, Nov. 9, 2025.

Additional Awards and Keynote Lectures

18. Italian Association for Research and Therapy of Eye Disorders (AIRCMO) Prize. Rome, Italy, Dec. 29, 2004.
19. 10th Earl P. Benditt Lecture. Univ. of Washington. Seattle, WA, Feb. 24, 2006.
20. Society for Medicines Research Award. London, UK, December 11, 2006.
21. C. Chester Stock Award Lecture. Memorial Sloan Kettering Cancer Center. New York, NY, May 10, 2007.
22. 2007 Biotech Hall of Fame. Special Recognition for Scientific Achievement. Laguna Niguel, CA, October 8, 2007.
23. Doctor *honoris causa*. University of Eastern Piedmont. Novara, Italy, October 11, 2007.
24. Annual Lerner Lecture. Cleveland Clinic. Cleveland, OH, Nov. 19, 2007.
25. Macula Society-Arnall Patz Award. Palm Beach, FL, March 28, 2008.

26. Michael A. O'Connor Award. Mayo Clinic Angiogenesis Symposium. Rochester, MN, October 24, 2008.
27. Eminent Lecture Series. National Cancer Inst. Bethesda, MD. February 23, 2009.
28. NDDO Honorary Award Lecture. Amsterdam, The Netherlands, March 23, 2009.
29. Stanley J. Korsmeyer Lecture. Venetian Inst. Mol. Med. Padua, Italy, May 6, 2009.
30. Mortel Lecturership in Cancer Research. Penn State University. Hershey, PA, August 20, 2009.
31. Macula Society-Michaelson Award. Tucson, AZ, February 27, 2010.
32. Jules Gonin Lecture. Retina Research Foundation. Kyoto, Japan, November 5, 2010.
33. Honorary Membership. Accademia Gioienia. Catania, Italy.
34. ARVO/AFER Special Recognition Award. Ft. Lauderdale, FL, April 30, 2011.
35. 5th Sayer Vision Research Lecture. National Eye Institute. Bethesda, MD, June 30, 2011.
36. Dean's Distinguished Lecture. Univ. of Kentucky College of Medicine. Lexington, KY, August 4, 2011.
37. Provost's Distinguished Lecture. MD Anderson Cancer Center. Houston, TX, October 18, 2011.
38. Juvenile Diabetes Research Foundation Award. San Francisco, CA, June 16, 2012.
39. Dean's Distinguished Lecture. Weill-Cornell Medical College. New York, NY, July 16, 2012.
40. Research Lecture at Nobel Forum. Stockholm, Sweden, October 18, 2012.
41. 91st Annual Beaumont Lecture. Michigan State Medical Society. Troy, MI, October 26, 2012.
42. The Economist Innovation Award (Bioscience). London, UK, November 15, 2012.
43. Elected Fellow. AACR Academy. Washington, D.C., April 5, 2013.
44. 21st Gifford Lecture. University of Nebraska Medical Center. Omaha, NE, May 23, 2013.
45. Klaus Hofmann Lecture. University of Pittsburgh School of Medicine. Pittsburgh, PA, October 4, 2013.
46. Priscilla White Lecturership. Joslin Diabetes Center-Brigham and Women Hospital. Boston, MA, February 13, 2014.
47. 2014 Lasker Lecture. American Physician Scientist Association Meeting. Chicago, IL, April 25, 2014.
48. Alkmeon International Prize. Rome, Italy, May 22, 2014.
49. Atena Prize. Rome, Italy, June 11, 2014.
50. Appointed to the Advisory Council of the Health Secretary of the Italian Republic, July 25, 2014.
51. Rell Sunn Award. Moores Cancer Center. La Jolla, CA, August 17, 2014.
52. Chancellor's lecture. Duke University. Raleigh Durham, NC, April 23, 2015.
53. Leslie Dana Gold Medal. St. Louis Society for the Blind and Visually Impaired. St. Louis, MO, April 25, 2015.
54. UCSF 150th Anniversary Alumni Excellence Award. San Francisco, CA May 30, 2015.
55. Hope Funds for Cancer Research Award. Newport, RI, June 27, 2015.
56. International Gold Award. Chinese Ophthalmological Society. Suzhou, China. Sept. 2016.
57. The TK Hunt lecture. Wound Healing Society. San Diego, CA April 5, 2017.
58. 25th Annual John F. Enders Lecture. Harvard Medical School, Boston MA October 21, 2018.
59. Web of Science Citation Laureate.
(<https://clarivate.com/webofsciencegroup/solutions/citation-laureates/>)
60. Mikamo Lecture. Japanese Circulation Society, Yokohama, Japan, March 30, 2019.
61. Stubenbord Visiting Professorship. Weill Cornell University, New York, NY, April 2019.
62. G.B. Bietti Medal. Italian Ophthalmological Society, Rome, Italy, May 25, 2019.
63. Inducted to Retina Hall of Fame, 2020.

64. Named Hildyard Endowed Chair in Eye Disease, UCSD, 2020.
65. Pair Prize for American-Italian Relations. Rome, Italy, October 3, 2021.
66. XIII Weinman Award in Cancer Research. Honolulu, HI, January 28, 2022.
67. Duane Roth Achievement Award. Moores Cancer Center, La Jolla, CA, April 27, 2023.
68. Hippocrates Prize. Medical Board of Catania. Catania, Italy, July 27, 2024.
69. University of California Irvine School of Medicine Dean's Distinguished Lecture, Irvine, CA, Sept. 17, 2024.
70. De Lay Keynote talk. 27th European Assoc. for Vision and Eye. Res. (EVER) Congress. Valencia, Spain. November 3-5, 2024.
71. University of California Drug Discovery Program Keynote talk. Riverside Campus, May 21st 2025.
72. iMed Conference® 17.0, Keynote talk. Lisbon Portugal. October 11-12, 2025.

Selected Advisory/Entrepreneurial Activities

1. Pezcoller Foundation-AACR International Award Jury Member (2006).
2. AACR Council of Scientific Advisers (2007-2014).
3. AACR Special Conferences Committee Member. (2009-).
4. Damon Runyon-Rachleff Innovation Award Committee Member (2007-2015).
5. North Am. Vascular Biol. Org. (NABVO) Scientific Advisory Board Member (2010-).
6. Humanitas Clinical Institute, Milan, Italy. Scientific Advisory Board Member (2012-).
7. The Economist Innovation Award, Jury Member (2013-2016).
8. Breakthrough Prize in Life Sciences, Selection Committee Member (2013-).
9. University of Padova, Italy, Strategic Projects Review Committee Member (2013).
10. Protelix, Inc., Scientific Advisory Board Member (2013-2017).
11. Data4Cure, Inc., Scientific Advisory Board Member (2013-2016).
12. Tiziana Life Sciences, Scientific Advisory Board (June 2014-).
13. Member of the Advisory Council to the Health Secretary of Italy (2014-2018).
14. Halozyme Inc., Scientific Advisory Board (2014).
15. Cancer Prevent. Res. Inst. of Texas (CPRIT). Cancer Biol. Sci. Peer Rev. Panel Member (2014-2016).
16. Zhongshan Ophthalmic Center (ZOC), Sun-Yat-Sen University, Guangzhou, Guangdong, China. Scientific Advisor (2016-2020).
17. Vitrisa Therapeutics. Board of Directors Member (2016-2019).
18. Inflammasome Therapeutics, Board of Directors Member (2017-).
19. Achaogen, Inc. Scientific Advisory Board Member (2017-2018).
20. DelMar Therapeutics, Board of Directors Member (2018-2020).
21. PharmAbcine, Scientific Advisory Board Member (2019-).
22. Atengen Pharmaceuticals, Scientific Advisory Board Member (2019-).
23. Camden-Nexus Venture Partner (2020-).
24. Kalaris (Theia) Therapeutics (co-founder).
25. NVasc Therapeutics (co-founder).

Ad hoc journal reviewer

American Journal of Pathology; Angiogenesis; Blood; Brain Research; British Journal of Cancer; Cancer Cell; Cancer Research; Cell; Cell Metabolism; Cell Reports; Cell Stem Cell; Circulation; Circulation Research; Clinical Cancer Research; Development; Developmental Cell; Diabetes; EMBO Journal; EMBO Reports; Endocrine Reviews; Endocrinology; Experimental Cell Research; Genes and Development; Human Gene Therapy; Journal of Biological Chemistry; Journal of Cell Biology; Journal of Clinical Endocrinology and Metabolism; Journal of Clinical Investigation; Journal of Experimental Medicine; Journal of Immunology; Journal of the National Cancer Institute; Kidney International; Molecular Biology of the Cell; Molecular and Cellular Biology; Nature; Nature Biotechnology; Nature Cell Biology; Nature Chemical Biology; Nature Communications; Nature Genetics; Nature Immunology; Nature Medicine; Nature Reviews Cancer; Nature Reviews Drug Discovery; Oncogene; PLoS Biology; Proceedings of the National Academy of Sciences, USA; Retina; Science; Science Signaling; Science Translational Medicine; Thrombosis and Hemostasis; Trends in Cardiovascular Medicine; Trends in Cell Biology.

Journal Editorial Board

Past or Present Board Member

Angiogenesis; Cancer Research; Cancer Discovery; Cardiac and Vascular Regeneration; Endothelium; Journal of Cardiovascular Pathobiology; Journal of Clinical Investigation; Lymphatic Research and Biology; Molecular and Cellular Oncology; Science Translational Medicine; Vascular Cell.

Editor-in-Chief

Molecular Cancer Therapeutics (2013-2018).

Invited presentations (2002-present)

2002

1. Keystone Symposium "Angiogenesis in cancer and other diseases". Banff, Alberta, Canada, Feb. 8-13, 2002.
2. Southwestern Oncology Group (SWOG) Meeting. Dallas, TX, April 20, 2002.
3. Cold Spring Harbor Symposium on Quantitative Biology "The Cardiovascular system". Cold Spring Harbor, N.Y., May 29-June 3, 2002.
4. Monte Verita' Angiogenesis Conference. Ascona, Switzerland, June 2-7, 2002.
5. Gordon Conference on Reproductive Biology. June 30-July 3, 2002.
6. European Renal Association Congress. Copenhagen, Denmark, July 14-17, 2002.
7. Annual Meeting Society for the Study of Reproduction. Baltimore, MD, July 27-31, 2002.
8. Gordon Conference on "Mechanisms of Hormone Action". Meriden, N.H., July 28-August 2, 2002.

9. First National Course "From Chemotherapy to molecular target". Parma, Italy, September 20-21, 2002.
10. 2nd International Symposium of the German Priority Research Program "Angiogenesis". Kloster Seeon, Germany, Sept. 21-24, 2002.
11. Second Interdisciplinary conference on Angiogenesis. Cascais, Portugal, October 12-15, 2002.
12. AAO-CME Symposium: "Leading edge therapies in neovascular retinal disease. Orlando, FL, October 19, 2002.
13. NCI Workshop "Growth Factors Roles in Metastasis". Bethesda, MD, October 19-22, 2002.
14. University of California, San Francisco. Nov. 6, 2002.

2003

15. "New Targets and Innovative Strategies in Cancer Treatment" Conference. Monte Carlo, February 7-8, 2003.
16. AACR Workshop. "Lessons learned: Translational issues for targeted drug development". Washington, D.C., March 10, 11, 2003.
17. Vascular biology seminar series. Harvard Med. School. Boston, MA. March 13, 2003.
18. Euroconference Angiogenesis. Institut Pasteur. Paris France, June 19-20, 2003.
19. 2nd Int. Conf. on "Molecular and Cell Biology Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease". Berlin, Germany, June 19-21, 2003.
20. Intl. Meeting "Angiogenesis in Cancer". Reykjavik, Iceland, June 26-28, 2003.
21. 94th AACR Annual Meeting. Washington, DC, July 11-14, 2003.
22. Gordon Conference on "Angiogenesis and Microcirculation". Newport, RH, August 10-15, 2003.
23. IBC's 8th Annual "Drug Discovery Technology 2003" Conference. Boston, MA, August 10-15, 2003.
24. Annual Congress Eur. Soc. Tissue Engineer. (ETES). Genova, Italy, September 3-6, 2003.
25. Cardiovascular Drug Discovery and Development Conf. San Diego, CA, Sept. 11-12, 2003.
26. IIIth Intl. Symposium on Atherosclerosis. Kyoto, Japan, Sept. 28-Oct. 2, 2003.
27. Oregon Natl. Primate Center/OHSU, October 3, 2003.
28. AACR Special Conference "New Directions in Angiogenesis Research". Chicago IL, October 15-19, 2003.
29. Japan Society of Clinical Oncology Meeting. Sapporo, Japan, Oct. 22-24, 2003.
30. 36th Annual Meeting. American Society of Nephrology. San Diego, CA, Nov. 15, 2003.

2004

31. Keystone Symposium "Angiogenesis: Novel Basic Science Insights and Human Therapy" (Organizer). Santa Fe, NM, January 13-18, 2004.
32. New York Acad. of Sciences Symposium "Anti-angiogenesis: therapeutic approaches to treating cancer: The perspective of 2004". New York, NY, January 27, 2004.
33. Developmental Vascular Biology Workshop. Asilomar, CA, Feb. 1-4, 2004.
34. Bascon Palmer Angiogenesis Conf. Miami, FL, Feb. 6-7, 2004.
35. Targeted Cancer Therapies: One Year of Progress. Nice, France, February 13-14, 2004.
36. S. Kimmel Cancer Conf. "Genomic Signaling and Tumor Targeting". San Diego, CA, Feb. 17, 2004
37. 26th Congress German Cancer Society. Berlin, Germany, March 1st, 2004.
38. AACR Annual Meeting. Orlando, FL, March 27-31, 2004.

39. Annual Meeting Japanese Soc. Gastroenterology. Sendai, Japan, April 22, 2004.
40. Beckman Symposium, "Cancer". Stanford Univ. Palo Alto, CA, April 30, 2004.
41. Annual Meeting Am. Acad. Pediatrics. San Francisco, CA, May 2, 2004.
42. New Therapeutic Perspectives for Colorectal Cancer. Olbia, Italy, May 22-23, 2004.
43. ASCO "Meet the expert on Avastin". New Orleans, LA, May 23, 2004.
44. Gordon Conference on "Endothelial Cell Phenotypes in Health and Disease". Andover, NH, August 22-27, 2004.
45. 3rd Intl. Kloster Seeon Meeting "Angiogenesis". Sept. 18-21, 2004.
46. Avastin Forum of Excellence. Amsterdam, NL, Sept 24-25, 2004.
47. Angiogenesis: New Opportunities and solutions. Cambridge, MA Sept 27-28, 2004.
48. Dartmouth Symposium for the Life Sciences. Hanover, NH, October 6, 2004.
49. TEDMED Conference. Charleston, SC. October 12-15, 2005.
50. First Intl. Conf. Soc. Integr. Oncol. New York, NY, Nov. 16, 2004.

2005

51. Keystone Symposium "Molecular Targets for Cancer Therapy". Santa Fe, NM, Jan 6-11, 2005.
52. Keystone Symposium "Meeting the challenge of drug discovery". Vancouver, B.C. Jan. 15-20, 2005.
53. 7th Meeting Assoc. Ocular Pharmacol. Ther. Catania, Italy, February 3-5, 2005.
54. UCSF Comprehensive Cancer Center. Feb. 18, 2005.
55. Avastin Symposium, Athens, Greece, March 11, 2005
56. Sidney Kimmel Cancer Center Conference "Molecular and Genetic Targeting for Cancer Imaging and Treatment". San Diego, CA, Feb. 27- March 2, 2005.
57. Lurie Cancer Center- Northwestern Univ. Chicago, IL, April 15, 2005.
58. 96th Annual Meeting AACR (Bruce F. Cain lecture). Anaheim, CA, April 16-20, 2005.
59. First Annual Conference of the ARVO/Pfizer Ophthalmics Research Institute. Angiogenesis, Neovascularization, and Vasoproliferation, Fort Lauderdale, FL, April 29-30, 2005.
60. Dept. of Biochemistry, Univ. of Texas Southwestern Medical School. Dallas, TX, May 5, 2005.
61. ASCO. President's Symposium. Orlando, FL, May 16, 2005
62. European School of Hematology Conf. on Angiogenesis, Barcelona, Spain, May 27-30, 2005.
63. The Endocrine Society, San Diego, CA, June 4, 2005
64. Annual Symposium Society for Toxicol. Pathol. (Keynote talk) Washington, D.C. June 20, 2005.
65. 39th Lake Kawaguchi Conference of Cardiology (Keynote talk). Tokyo, Japan. July 9-10, 2005.
66. Salk/EMBL Oncogene Meeting (Keynote talk). La Jolla, Ca August 13-15, 2005.
67. Gordon Conference on "Angiogenesis and Microcirculation" Newport, RI, August 14-19, 2005.
68. 3rd Eur. Meeting on Vascular Biology and Medicine. Hamburg, Germany, September 28-30, 2005.
69. 2nd Intl. Conf. on Angiogenesis. Monte Verita' Conf. Center (Keynote talk). Ascona, Switzerland, October 1-5, 2005.
70. AACR/NCI/EORTC Intl. Conf. Molecular Targets and Cancer Therapeutics (Keynote talk). Philadelphia, PA, Nov. 14-18, 2005.
71. Symposium on antiangiogenesis. Taipei, Taiwan, Nov. 26, 2005.
72. UCSF Pulmonary Grand Rounds. San Francisco, CA, Dec. 6, 2005.

- 73. Abelson Symposium AAAS. Washington, DC, December 8, 2005.
- 74. Lombardy Ophthalmologic Society Meeting. (Keynote talk) Milan, Italy, December 16-17, 2005.

2006

- 75. Keystone Symposium "Hypoxia and Development, Physiology and Disease" (Keynote talk). Breckenridge, CO, Jan. 16-21, 2006.
- 76. Second Developmental Vascular Biology Workshop. Asilomar, CA, Feb. 1-4, 2006.
- 77. Bascon Palmer Conference on Angiogenesis. Miami, FL, February 3-4, 2006.
- 78. Miami Nature Biotechnology Winter Symposium. Miami, FL, February 4-8, 2006.
- 79. E.P. Benditt Lecture. Univ. of Washington. Seattle, WA, February 22, 2006.
- 80. Roche Symposium on anti-angiogenesis. Antalya, Turkey, March 4, 2006.
- 81. President's Symposium. The Microcirculatory Society. San Francisco, CA, April 1-5, 2006.
- 82. AACR Annual Meeting. Washington, DC, April 5-, 2006.
- 83. 2006 Passano Foundation Lecture. Johns Hopkins Univ. Baltimore, MD, April 25, 2006.
- 84. 16th ESH conference on Angiogenesis. Mandelieu, Cannes, France, May 13-16, 2006.
- 85. General Motors Cancer Research Awards Annual Scientific Conference "Genomics and Cancer". Bethesda, MD, June 12-13, 2006.
- 86. 20th IUBMB Symposium. Kyoto, Japan, June 18-23, 2006.
- 87. Pezcoller Foundation Symposium. Trento, Italy, June 27-29, 2006.
- 88. Gordon Conf. "Cancer Models and Mechanisms". Smithfield, R. I., July 30- August 4, 2006.
- 89. Gordon Conf. "Endothelial cell phenotypes in health and disease". Biddeford, ME, August 6-11, 2006.
- 90. Gordon Conf. on Drug Carriers in Medicine and Biology (Keynote talk) Big Sky, MT, Aug. 20-26, 2006.
- 91. Symposium "Targeted Therapies In Cancer: Myth or Reality?" Milano, Italy Sept. 4, 5, 2006.
- 92. Intl. Conf. "New therapies in retinal diseases" (Keynote talk). Rome, Italy, Sept. 7-8, 2006.
- 93. Angiogenesis Symposium. Maastricht, NL, Sept. 15, 2006.
- 94. American Academy of Ophthalmology Subspecialty Day- The Retina. Las Vegas NV, Nov. 10-11, 2006
- 95. 2006 Advanced Retinal Therapy Meeting. Vienna, Austria, Nov. 18, 2006.
- 96. Society for Medicines Research (Award lecture). London, UK, Dec. 11, 2006.

2007

- 97. 7th AACR/JCA Joint Intl. Conf. Waikoloa, HI, Jan. 21-25, 2006.
- 98. Memorial Sloan-Kettering Cancer Center. C. Chester Stock Award Lecture. New York, NY, February 14, 2007.
- 99. Bascon Palmer Eye Inst. Conf. Angiogenesis 2007. Miami, FL, February 23-24, 2007.
- 100. Keystone Symposium "Stem Cell Interactions with their Microenvironmental Niche". Keystone, CO Mar 2 -7, 2007.
- 101. 2007 Society for Gynecological Investigation Annual Meeting. Las Vegas, NV, March 14-17, 2007.
- 102. Pathology Days. Ede-Wageningen, The Netherlands, April 10-11, 2007.
- 103. AACR Annual Meeting. Los Angeles, Ca, April 14-18, 2007.
- 104. 2nd International UCSF Conference on "Cancer and the Lymphovascular System: Basis for Rational Therapy"(Distinguished lecture). San Francisco, CA, May 4, 2007.
- 105. Seventh ESH conference on Angiogenesis. Praia de Santa Eulália, Portugal May 11-14, 2007.

106. ASCO "Science of Oncology" Award lecture. Chicago, IL, June 4, 2007.
107. Reggio Retina 2007 Meeting. Reggio Calabria, Italy, June 7-9, 2007.
108. ESMEC-European School of Medicinal Chemistry-Urbino. (XXVII Advanced Course of Medicinal Chemistry and "E. Duranti" Seminar for PhD students) Urbino, Italy, July 1-6, 2007.
109. Associazione Italiana di Oncologia Medica (AIOM) Congress (Keynote talk). Palermo, Italy, October 12-16, 2007.
110. Gairdner Foundation Symposium. Toronto, Canada, October 25-26, 2007.
111. Annual Lerner Lecture. Cleveland Clinic. Cleveland OH, Nov. 19, 2007.
112. 38th International Symposium of the Princess Takamatsu Cancer Research Fund. Tokyo, Japan, Nov. 27-29, 2007.

2008

113. Moores UCSD Cancer Center. Director's Seminar Series. La Jolla, CA, January 9th, 2008.
114. CNIO Cancer Conference: "Development and Cancer". Madrid, Spain, February 4-6, 2008.
115. Nobel Forum, Karolinska Institutet. "Novel Targeted Cancer Therapies: from cells and mice to patients". Stockholm, Sweden, March 6-7, 2008.
116. USA/Japan Workshop on Tumor Angiogenesis and Lymphangiogenesis (Co-organizer). Kyoto, Japan, March 19-21, 2008.
117. AACR Annual Meeting. San Diego, CA, April 12-16, 2008.
118. NCI Seminar. Bethesda, MD, April 28, 2008.
119. Second Annual Dr. Bruce I. Terman Memorial Lecture. Albert Einstein College of Medicine. New York, NY, April 30, 2008.
120. ESH Conference on Angiogenesis. Paris, France, May 9-12, 2008.
121. "Humanitas lecture". Humanitas Clinical Institute and Research Foundation. Milan, Italy, May 13, 2008.
122. First International Conference "Translational Research in Oncology", Forlì, Italy, May 14-17, 2008.
123. Pezcoller Foundation Symposium, Trento, Italy June 11-13, 2008.
124. 2008 Endocrine Society Annual Meeting. San Francisco, CA, June 17, 2008.
125. 14th Samsung International Symposium on Molecular Medicine. Seoul, Korea, September 26, 2008.
126. UCSF Biomedical Sciences Seminar Series. San Francisco, CA, October 22, 2008.
127. 3rd Mayo Clinic Angiogenesis Symposium. Rochester, MN, October 24-26, 2008.
128. Technion University, Haifa, Israel, November 2, 2008.
129. AACR Centennial Conference "Translational Cancer Medicine 2008: Bridging the Lab and the Clinic in Cancer Medicine" (Judah Folkman Memorial Lecture). Jerusalem, Israel, November 3-6, 2008.
130. National Cancer Day. Rome, Italy, Nov. 8, 2008.
131. 24th Kumamoto Medical Bioscience Symposium. Kumamoto, Japan, November 27, 2008.

2009

132. Keystone Symposium "Angiogenesis and Lymphangiogenesis in Cancer". Big Sky, MT, January 6-11, 2009.
133. 2009 ASCO Gastrointestinal Cancer Symposium. San Francisco, CA, January 15-17, 2009.
134. Japanese Microcirculation Society (Keynote talk). Tokyo, Japan, February 20, 2009.
135. National Cancer Institute (Eminent Lecture Series). Bethesda, MD, February 23, 2009.
136. Cell Press Lablink Symposium on Epithelial Biology. San Francisco, CA, March 18, 2009.
137. 7th Intl. Symposium on Targeted Anticancer Therapies. Amsterdam, The Netherlands, March 23-25, 2009.

138. VEGF Conference. Paris, France, March 27-28, 2009.
139. AACR Annual Meeting. Denver, CO, April 18-22, 2009.
140. 3rd International Symposium "Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy". San Francisco, CA, May 6-9, 2009.
141. Raffaele Tecce Memorial Lecture. Regina Elena Cancer Inst. Rome, Italy, May 4, 2009.
142. Stanley J. Korsmeyer Lecture. Venetian Inst. Mol. Med. Padova, Italy, May 6, 2009.
143. Gordon Research Conf. on Angiogenesis. Newport, RI, August 2-7, 2009.
144. Penn State Hershey Cancer Center. August 20, 2009.
145. 7th International Symposium on the Biology of Endothelial Cells. Vienna, Austria Sept. 2-5, 2009.
146. Aspen Institute Italy. Cernobbio, Italy, September 27-28, 2009.
147. Distinguished Seminar Series. H. Irving Comprehensive Cancer Center, Columbia Univ. New York, NY, October 14, 2009.
148. Angiogenesis: A Key Target in Oncology Course (Keynote lecture) Barcelona, Spain, October 30, 2009.
149. Annual "Moving Targets" Symposium. AAPS/USC Chapter. Los Angeles, CA, Nov. 7, 2009.
150. 51st Annual Meeting Am. Soc. Hematology. New Orleans, LA, Dec. 5-6, 2009.

2010

151. Keystone Symposium "Advances in Biopharmaceuticals" (Keynote talk). Midway, UT, Jan 8-13, 2010.
152. "Oncology at the Limits" Symposium. Cape Town, South Africa, Jan. 29-Feb. 1, 2010.
153. Keystone Symposium "Role of inflammation in oncogenesis". Keystone, CO, February 7-10, 2010.
154. Macula Society-Michaelson Symposium. Tucson, AZ, February 24-27, 2010.
155. Universidad Nacional Autonoma de Mexico. Campus UNAM-Uriquilla. March 12, 2010.
156. International Academy for Advanced Oncology. Kickoff forum. Tokyo, Japan, March 26-27, 2010.
157. UCSF Cancer Club. San Francisco, CA April 12, 2010.
158. Banbury Conference "Tumor Microenvironment and Metastasis". Cold Spring Harbor, NY, May 5-7, 2010.
159. New York Academy of Sciences Symposium "Toward Personalized Cancer Medicine". Barcelona, Spain, May 19-21, 2010.
160. San Francisco State University. "Personalized Medicine 3. Targeting cancer" (Keynote talk). San Francisco, CA, May 25, 2010.
161. MD Anderson Cancer Center. Houston, TX, June 2, 2010.
162. 16th Intl. Vascular Biology Meeting. Los Angeles, CA, June 20-24, 2010.
163. IBC Conference "Targeting the tumor microenvironment" San Francisco, CA, August 2-4, 2010.
164. Berkeley's annual Bay Area Vision Research Day (BAVRD 2010). Berkeley, CA, August 17, 2010.
165. 4th Mayo Clinic Angiogenesis Symposium. Mackinac Island, MI, August 27-29, 2010.
166. 12th International Workshop on Multiple Endocrine Neoplasia (MEN2010). Gubbio, Italy, September 16-18, 2010.
167. Retina Society Meeting. San Francisco, CA, September 25, 2010.
168. Intl. Conference "Regulatory Myeloid Cells in Health and Disease" (Keynote talk). Arlington, VA, October 21-24, 2010.
169. Retina Research Foundation Symposium. Kyoto, Japan, Nov. 3-6, 2010.
170. Frontiers in Cancer Science 2010. November 8-10, 2010, Singapore.
171. Burnham Institute. Cancer Center Seminar Series. La Jolla, CA, Dec. 6, 2010.

2011

172. Champalimaud Foundation Symposium. Lisbon, Portugal, January 14-15, 2011.
173. 7th Annual Pathway-Targeted Therapies in Cancer. Cambridge Healthtech Inst. San Francisco, CA February 25, 2011.
174. 10th Macular Vision Research Foundation (MVRF) Symposium. New York, NY, March 24-27, 2011.
175. AACR Annual Meeting. Orlando, FL, April 2-6, 2011.
176. Weill Cornell Medical College. Postdoctoral Research Day (Keynote lecture) New York, NY, April 6, 2011.
177. UCLA IMED seminar series. Los Angeles, CA May 4, 2011.
178. DFG Meeting. Hinterzartener Group for Cancer Research. Villa Collina, Cadenabbia, Lake Como, Italy, May 12-15, 2011.
179. Cold Spring Harbor-Asia Conference. Translational Approaches to Cancer. Suzhou, Dushu Lake, People's Republic of China, May 24-28, 2011.
180. 1st Beijing International Symposium on Tumor Angiogenesis and Tumor Microenvironment. Tsinghua University. Beijing, People's Republic of China, May 28-June 2, 2011.
181. 8th International Duodecim Symposium on "Endothelial growth factors in cancer and cardiovascular diseases". Vanajanlinna, Hämeenlinna, Finland June 9-11, 2011.
182. 5th Sayer Vision Research Lecture. Bethesda, MD, June 30, 2011.
183. 6th Annual National MD/PhD Student Conference (Keynote talk). Keystone, CO, July 15-17, 2011.
184. Dean's Distinguished Lecture. Univ. of Kentucky College of Medicine. Lexington, KY, August 4, 2011.
185. ISREC Symposium 2011. Lausanne, Switzerland, September 7-10, 2011.
186. Basel Signaling Symposium. Basel, Switzerland, September 11-13, 2011.
187. Paul Janssen Award Symposium. New York Academy of Sciences. New York, NY, September 14, 2011.
188. 35th National Congress, Italian Society of Pharmacology. Bologna, Italy, September 16, 2011.
189. 6th Annual Frontiers of Clinical Investigation: Bench to Bedside Symposium (Keynote talk), La Jolla, CA, October 13-15, 2011.
190. Provost Distinguished Lecture. MD Anderson Cancer Center. Houston, TX, October 18, 2011.
191. 2nd Pacific Symposium on Angiogenesis. Jeju Island, South Korea, October 30-November 1, 2011.
192. 2011 YBRI Intl. Symposium. Seoul, South Korea, Nov. 3, 2011.
193. IBC's 8th Antibody Therapeutics conference (Keynote talk). San Diego, CA, December 6, 2011.
194. UCSF Cancer Center Seminar Series. San Francisco, CA, December 9, 2011.

2012

195. Keystone Symposium "Angiogenesis: advances in basic science and therapeutic applications" (Organizer). Snowbird Resort, UT, January 16-21, 2012.
196. Morgagni Commemorative Symposium. Padova, Italy, March 23-24, 2012.
197. AACR Annual Meeting. Chicago, IL, March 31-April 4, 2012.
198. Center for Translational Medicine Meeting. Shanghai, China, April 13-15, 2012.
199. Moores UCSD Cancer Center. La Jolla, CA, April 19, 2012.
200. Eureka 4th Annual International Certificate Program in Translational Medicine. Siracusa, Italy, May 5-8, 2012.

- 201. Keystone Symposium “The role of inflammation in carcinogenesis”. Dublin, Ireland, May 20-25, 2010.
- 202. 17th Intl. Vasc. Biol. Mtg. (IVBM 2012). Wiesbaden, Germany, June 2-5, 2012.
- 203. Gordon Res. Conf. “Endothelial Phenotypes” (Keynote talk). Il Ciocco, Lucca, Italy, July 30-August 3, 2012.
- 204. 5th Mayo Clinic Angiogenesis Symposium. Minneapolis, MN, August 17-19, 2012.
- 205. 7th Chinese Conference on Oncology. Beijing, People’s Republic of China, September 6-9, 2012
- 206. FEBS Workshop: Molecular and Cellular Mechanisms in Angiogenesis, Capri, Italy, October 14-17, 2012.
- 207. Research lecture at Nobel Forum. Stockholm, Sweden, October 18, 2012.
- 208. Uppsala University seminar. Uppsala, Sweden, October 19, 2012.
- 209. 91st Annual Beaumont Lecture. Michigan State Medical Society. Troy, MI, October 26, 2012.

2013

- 210. 15th Intl. Symposium on Anti-Angiogenic Agents. La Jolla, CA Jan. 31-Feb. 2, 2013.
- 211. “Ophthalmology Update 2013” (Keynote talk). La Jolla, CA Feb. 16-17, 2013.
- 212. Annual retreat. Vision Discovery Institute, Georgia Health Sciences University, Augusta, GA (Keynote talk). March 14-15, 2013.
- 213. 2013 Tumor microenvironment symposium. Mayo Clinic. Rochester, MN, April 15, 2013.
- 214. Turkish National Cancer Congress. Antalya, Turkey, April 19-20, 2013.
- 215. European Brain Research Institute Symposium in Memory of Rita Levi-Montalcini. Rome, Italy, April 21-22, 2013.
- 216. Trans-NIH workshop on angiogenesis (Keynote talk). Bethesda, MD, May 20-21, 2013.
- 217. 21st Gifford lecture. University of Nebraska Medical Center. Omaha, NE, May 23, 2013.
- 218. Korea Cancer Association Satellite Symposium (Keynote talk). Seoul, Korea, June 14, 2013.
- 219. 16th Annual San Diego MedChem Symposium. UCSD, July 12, 2013
- 220. Peking University-Bio Symposium (Keynote talk) La Jolla, July 20, 2013.
- 221. Tumor models 2013 (Keynote talk). Boston, MA, July 25-26, 2013.
- 222. NABVO. *Vasculata* 2013 (Keynote talk). San Diego, CA, July 29, 2013.
- 223. Gordon Res. Conf. “Angiogenesis “. Newport, RI, August 3-4, 2013.
- 224. 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (Keynote talk). Geneva, Switzerland, August 28-30, 2013.
- 225. 13th Euretina Congress. Hamburg, Germany. Sept. 26-29, 2013.
- 226. 28th Harvard Medical School Annual Course on Tumor Microenvironment. Boston, MA Sept. 30-Oct. 3, 2013.
- 227. Klaus Hofmann Lecture. University of Pittsburgh School of Medicine. Pittsburgh, PA, October 4th, 2013.
- 228. ISSNAF Annual Meeting. Washington, D.C., October 28-29, 2013.
- 229. 7th Annual Frontiers of Clinical Investigation Symposium. La Jolla, CA, Nov. 4-6, 2013.
- 230. Sino-U.S. Conference on Medicine in the 21st Century. Shanghai, People’s Republic of China, November 16-17, 2013.
- 231. Therapeutic Innovation in Ovarian Cancer Symposium (Keynote talk). Milano, Italy, November 22-23, 2013

2014

- 232. 2014 Guangdong International Forum of Ophthalmology (Keynote talk). Guangzhou, People’s Republic of China, January 11, 2014.

233. West China Medical School of Sichuan University. Chengdu, People's Republic of China, January 13, 2014.
234. 16th Intl. Symposium on Anti-Angiogenic Agents. La Jolla, CA, Feb. 6-8, 2014.
235. Priscilla White Lecturership. Joslin Diabetes Center-Brigham and Women Hospital. Boston, MA, February 13, 2014.
236. AACR Special Conference "Cellular Heterogeneity in the Tumor Microenvironment". San Diego, CA, Feb. 26-March 1, 2014.
237. Keystone Symposium "Inflammation, Infection and Cancer". Whistler, B.C., Canada. March 9-14, 2014.
238. 87th Annual Meeting, Japanese Pharmacological Society. Sendai, Japan, March 21, 2014.
239. Inaugural UCSD MSTP Research Symposium (Keynote talk). La Jolla, CA, March 26, 2014.
240. 2014 International forum on Antiangiogenic Therapy, Shanghai, People's Republic of China, April 13, 2014.
241. 18th International Vascular Biology Meeting (IVBM). Kyoto, Japan. April 14-17, 2014.
242. 2014 Lasker APSA lecture. Chicago, IL, April 25, 2014.
243. Progress in the Science of Medicine (PRISM) lecture. La Jolla, CA, May 19, 2014.
244. Frontiers in Translational Cancer Research Meeting. Helsinki, Finland, June 8-10, 2014.
245. Second International Congress on "Advances in Biology and Treatment of Malignant Brain Gliomas". Rome Italy June 12-14, 2014.
246. New York Academy of Sciences Symposium "Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy". New York, NY, June 19-20, 2014.
247. "Best of ASCO". Shanghai, July 14, 2014.
248. Genentech, Inc. Seminar. July 24, 2014.
249. 6th Mayo Clinic Angiogenesis and Tumor Microenvironment Symposium: From Basic Science and Clinical Challenges to Patient Care. Rochester, MN, August 22-24, 2014.
250. Anti-Angiogenesis Symposium. Kyoto, Japan, September 5, 2014.
251. Chugai Anti-Angiogenesis Forum. Tokyo, Japan, September 6, 2014.
252. Gairdner Symposium. Toronto, Canada, October 30th, 2014.
253. Buck Research Institute on Aging. Novato, CA, December 19, 2014.

2015

254. Gordon Research Conference on Vascular Cell Biology (Keynote talk). Ventura, CA, January 18-25, 2015.
255. Oklahoma Medical Foundation. Oklahoma City, OK, February 11, 2015.
256. Danny Thomas lecture, St. Jude Children's Research Hospital. Memphis, TN, February 13, 2015.
257. IPSEN Foundation Cancer Science Meeting "Tumor Heterogeneity and Microenvironment". Mysore, India, February 28-March 3, 2015.
258. AACR Special Conference on Angiogenesis. Orlando, FL, March 5-8, 2015.
259. EMBO/EMBL Symposium 'Frontiers in Stem Cells and Cancer'. Heidelberg, Germany. March 29-31, 2015.
260. Chancellor's lecture. Duke University. Raleigh Durham, NC, April 23, 2015.
261. Washington University. Dept of Ophthalmology. St. Louis, MO, April 25, 2015.
262. Anti-Angiogenesis Symposium. Univ. of Catania Medical School. Catania, Italy, April 28-29, 2015.
263. Champalimaud lecture. ARVO, Denver, CO, May 5, 2015.
264. World Medicine Summit. Macau, People's Republic of China, July 7-9, 2015.
265. Chinese Medical Association Meeting. Chongqing, People's Republic of China. July 10-11, 2015.

266. International Society of Ocular Cell Biology (Keynote talk). Guangzhou, People's Republic of China, August 7-9, 2015.
267. World Congress of Lymphology, San Francisco, CA, September 7-11, 2015.
268. DKFZ-ZMBH Alliance Forum 2015 "Tumor microenvironment, Metabolism and Metastasis". Heidelberg, Germany, Sept. 28-30, 2015.
269. IX International Meeting, Bietti Foundation: New Diagnostic and Therapeutic Frontiers in Ophthalmology. Rome, Italy, October 2-4, 2015.
270. Italian Society of Hospital Pharmacology (SIFO Annual Meeting (Keynote talk). Catania, Italy, October 22-25, 2015.
271. Italian Society of Pharmacology (SIF) Annual Meeting (Keynote talk). Naples, Italy, October 27-30, 2015.
272. VisionServe Alliance Meeting. La Jolla, CA, November 3rd, 2015.
273. Breakthrough Prize Symposium. UC Berkeley. Berkeley, CA, November 9, 2015.

2016

274. Cincinnati Children's Hospital, Division of Developmental Biology. Cincinnati, OH, February 3rd, 2016.
275. 18th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer: Recent Advances and Future Directions in Basic and Clinical Cancer Research. La Jolla, CA, February 4-6, 2016.
276. Taipei Inst. of Biomedical Sciences, Retreat. Taipei, Taiwan, March 9-11, 2016.
277. UC San Diego-Kyoto University Joint Symposium. La Jolla, CA, March 14-15, 2016.
278. Argentinean Ophthalmology Society, Buenos Aires, Argentina, March 29-April 1, 2016.
279. Seminar. Northwestern University, Chicago, IL, May 12-14, 2016.
280. Seminar. Dept. of Ophthalmology, McGill University, Montreal, Canada, May 26, 2016.
281. 35th C. McCulloch lecture. Dept. of Ophthalmology. Univ. of Toronto. Toronto, Canada, May 27, 2016.
282. Keystone Symposia. "Exosomes/Microvesicles, Novel Mechanisms of Cell-Cell Communication". Keystone, CO, June 19-23, 2016.
283. Chinese Ophthalmology Society Meeting. Beijing, People's Republic of China. Sept. 7-9, 2016.
284. Kloster Seeon Young Investigator Meeting & 9th International Kloster Seeon Meeting "Angiogenesis". Munich, Germany, September 15-20, 2016.
285. Johns Hopkins University. Wilmer Science Seminar Series, Baltimore, Maryland, October 17, 2016.
286. Japanese Clinical Ophthalmology Meeting. Kyoto, Japan, November 3-6, 2016.
287. Mayo Clinic Angiogenesis Symposium, Jacksonville, FL, November 17-20, 2016.
288. Pharmacology Seminar Series. University of California San Diego. La Jolla, CA, 92093

2017

289. San Raffaele Institute Retreat. Baveno, Italy, March 10-12, 2017.
290. AACR Annual Meeting, Washington, DC, April 2-5, 2017.
291. 2017 T. K. Hunt Lecture. The Wound Healing Foundation. San Diego, CA, April 5, 2017.
292. Chinese Vascular Biology Organization (CVBO) Meeting, Guangzhou, People's Republic of China, June 24-25, 2017.
293. 2017 Lipari International Summer School in Computational Life Sciences. Lipari, Italy, July 10-15, 2017.
294. Gordon Research Conference on "Angiogenesis and Microcirculation". Newport, RI, August 6-11, 2017.

- 295. Korean Academy Science and Technology Forum. Seoul, South Korea, October 31-November 1, 2017.
- 296. Inaugural APVBO Conference. Guangzhou, People's Republic of China, Nov 13-17, 2017.
- 297. Weinman Symposium. Honolulu HI, Nov. 30-Dec. 1, 2017.

2018

- 298. 5th Gavin Herbert Eye Institute "Bench to Bedside Research Symposium. Irvine, CA March 23, 2018.
- 299. Pathology Ground Rounds. Yale University. May 10, 2018
- 300. 20th International Vascular Biology Meeting (IVBM 2018). Keynote talk. Helsinki, Finland, June 3-7, 2018.304.
- 301. Lipari School on Computational Sciences. Lipari, Italy July 25-31, 2018.
- 302. Banbury Conference. Diverse effects of neutrophils in cancer. Cold Spring Harbor, November 27-30, 2018.
- 303. YES Meeting, Porto, Portugal, September 13, 2018.
- 304. University of California San Francisco, September 24, 2018.
- 305. 5th Annual John F. Enders Lecture. Harvard Medical School, Boston MA March 21, 2018.
- 305. Kobe International Symposium on Drug Discovery. Kobe, Japan, October 19, 2018.
- 306. MD Anderson Cancer, Houston TX, Dec. 12, 2018.

2019

- 307. 2019 Vascular Biology Gordon Research Seminars (GRS) "Frontiers in Vascular Cell Communication: Implications in health and disease" (Keynote talk). Ventura, CA, January 19-20, 2019
- 308. Mikamo lecture. 83rd Annual Scientific Meeting Japanese Circulation Society. Yokohama, Japan, March 29-31, 2019.
- 309. PRISM lecture. UCSD. March 11, 2019.
- 310. Asia Pacific Vascular Biology Organization (APVBO) Conference 2019, Guangzhou, People's Republic of China, May 9-12, 2019.
- 311. G.B. Bietti award lecture, Rome, Italy May 24, 2019
- 312. Ho-Am Forum on Medicine 2019. Seoul, South Korea, May 29, 2019.
- 313. 15th Symposium Young Scientist Association Symposium. Medical University of Vienna. Vienna, Austria, June 13-14, 2019.
- 314. IBSA Foundation Forum: "Revolutionary therapies for cancer: meet the giants of oncology research". Lugano, Switzerland, June 21st. 2019.
- 315. Lipari School of Computational Life Sciences. Lipari, Italy, July 25-29, 2019.
- 316. World Scientists Forum. Sanya, People's Republic of China, Aug. 21-24, 2019.
- 317. BioGene Inc., Seminar Series. San Mateo, CA October 16, 2019.
- 318. Cardiovascular Research Institute (CVRI) Seminar. Univ. of California San Francisco, October 17, 2019.
- 319. International Conference on Regenerative Medicine. Keynote talk. Moscow, Russia, November 23-29, 2019.

2020

- 320. Weinman Symposium, Univ, of Hawaii, Honolulu, January 22-26, 2020.
- 321. Cygnal Therapeutics Seminar, July 20, 2020.

2021

- 322. 1st annual Conference Delivering Discoveries: Updates in Oncology. La Jolla, CA, October 29, 2021.
- 323. Univ. of Illinois seminar series, November 22, 2021
- 324. The Isaiah Fidler Lecture. MD Anderson Cancer Center, Dec. 17, 2021.

2022

- 325. 13th Weinman Symposium, Univ. of Hawaii, Honolulu January 25-29, 2022.
- 326. Baylor College of Medicine, Vision Seminar, April, 5, 2022.
- 327. Lipari School of Computational Biology, Lipari, Italy, July 23-30, 2022.
- 328. 22nd NABVO, Oakland CA, October 13-17, 2022.
- 329. Annual Research Day, Dept of Ophthalmology, Univ. of Montreal. October 21-22, 2022
- 330. 2nd annual Conference "Delivering Discoveries: Updates in Cancer Care", La Jolla CA October 27, 2022.
- 331. VII International Congress "Clinical Needs and Translational Research in Oncology" Reggio Emilia, Italy, Nov. 24-25, 2022.

2023

- 332. Gordon Conference: Vascular Cell Biology: Vascular Complexity, heterogeneity, and Metabolism in Health and Disease". Ventura CA, Jan.15-20, 2023.
- 333. 14th Weinman Symposium, Univ. of Hawaii, Honolulu, January 25-29, 2023.
- 334. Vascular permeability workshop. Berlin, Germany, April 12-14, 2023.
- 335. Byers Eye Research Institute. Stanford University, Palo Alto, CA April 21, 2023.
- 336. Cellular Therapies and Transfusion Medicine in Trauma and Critical Care. Scottsdale, AZ May 9-11, 2023.
- 337. Lipari School on Computational Life Sciences. Lipari, Italy, July 23-29, 2023.
- 338. Gordon Conference on Angiogenesis and angiostability in development, disease and engineered tissues. Newport RI, July 30th-August 4th, 2023.
- 339. XVI Congress Association for Ocular Pharmacology. Keynote talk, Indianapolis, IN August 11, 2023.
- 340. Calico Life Sciences, Seminar. South San Francisco, CA, October 27, 2023.
- 341. Solid Tumor Therapeutics seminar series, UCSD, La Jolla CA October 13, 2023.
- 342. World Laureate Association (WLA) Forum. Shanghai, People's Republic of China, November 6-8, 2023.
- 343. Keio Medical Sciences Prize lecture. Tokyo, Japan, Nov. 9, 2023.

2024

- 344. Prince Mahidol Award Lecture. Bangkok, Thailand, January 24, 2024
- 345. 20th Anniversary Vascular Developmental Biology Virtual Workshop. February 12-14, 2024.
- 346. Investing in Cures Summit. Scottsdale, AZ, March 8-9, 2024.
- 347. APVBO 2024. Guangzhou, People's Republic of China. April 5-8, 2024.
- 348. China Pharmaceutical University, Nanjing, People's Republic of China. April 13, 2024.
- 349. Web of Life Conference. University of Oklahoma, Oklahoma, OK, April 25-26, 2024.
- 350. 8th Annual Cardiovascular Bioengineering Symposium. Houston, TX, May 22-25, 2024.
- 351. Lipari School on Computational Life Sciences. Lipari, Italy, July 21-27, 2024.
- 352. 27th European Assoc. for Vision and Eye. Res. (EVER) Congress. De Lay Keynote talk. Valencia, Spain. November 3-5, 2024.

2025

353. University of California Drug Discovery Program, Keynote talk. Riverside Campus, May 21st 2025.
354. Lipari School on Computational Life Sciences. RNA Biology and Comparative Genomics for Medicine. Lipari, Italy, July 13-19, 2025.
355. iMed Conference® 17.0, Keynote talk. October 11-12, 2025, Lisbon, Portugal.

Publications

(Total citations (Google Scholar): > 210,000; h-index: 189).

<https://scholar.google.com/citations?user=WPJnV70AAAAJ&hl=en&oi=ao>

Original articles

1. Nicoletti, F, Patti, F, Ferrara, N, Canonico, PL, Giammona, G, Scapagnini, U. Comparative effects of estrogens and prolactin on GAD activity in different brain areas. **Brain Res.** 232, 238-241, 1982.
2. Nicoletti, F, Ferrara, N, Patti, F, Viglianesi, M, Rampello, L, Bianchi, A, Scapagnini, U. Influence of sex steroids and prolactin on haloperidol-induced catalepsy. **Brain Res.** 279, 352-358, 1983.
3. Speciale, C, Ferrara, N, Sortino, MA, Bernardini, R, De Simone, D, Marano, P. Neuroendocrine modulation of haloperidol-induced catalepsy. **Boll. Soc. Ital Biol. Sper.** 59, 51-57, 1983.
4. Ferrara, N, Bernardini, R, Nicoletti, F, Drago, F, Matera, M, Scapagnini, U. Prolactin influences sexual behavior during aging. **J. Endocrinol. Invest.** 8 (2), 23-32, 1985.
5. Ferrara, N, Fujii, DK, Goldsmith, PG, Widdicombe J, Weiner R. Transport epithelial characteristics of cultured bovine pituitary follicular cells. **Am. J. Physiol.** 252, E304-312, 1987.
6. Ferrara, N, Schweigerer, L, Neufeld, G, Mitchell, R, Gospodarowicz, D. Pituitary follicular cells produce basic fibroblast growth factor. **Proc. Natl. Acad. Sci. USA.** 84, 5773-5777, 1987.

7. Neufeld, G, Ferrara, N, Schweigerer, L, Mitchell, R, Gospodarowicz, D. Bovine granulosa cells produce basic fibroblast growth factor. *Endocrinology*. 121, 597-603, 1987.
8. Schweigerer, L, Ferrara, N, Haaparanta, T, Neufeld, G, Gospodarowicz, D. Basic fibroblast growth factor: expression in cultured cells derived from corneal endothelium and lens epithelium. *Exp. Eye Res.* 46, 71-80, 1988.
9. Gospodarowicz, D, Ferrara, N, Neufeld, G, Haaparanta, T. Basic fibroblast growth factor: Expression in vascular smooth muscle cells. *Eur. J. Cell Biol.* 41, 144-151, 1988.
10. Ferrara, N, Ousley, F, Gospodarowicz, D. Bovine brain astrocytes express basic fibroblast growth factor, a neurotropic and angiogenic mitogen. *Brain Res.* 462, 223-232, 1988.
11. Ferrara, N, Gospodarowicz, D. Regulation of ion transport in hypophyseal pars intermedia follicular cell monolayers. *Biochem. Biophys. Res. Commun.* 157, 1376-1382, 1988.
12. Ferrara, N, Henzel, WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem. Biophys. Res. Commun.* 161, 851-858, 1989.
13. Leung, DW, Cachianes, G, Kuang, W-J, Goeddel, DV, Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 246, 1306-1309, 1989.
14. Rosenthal, RA, Megyesi, JF, Henzel, WJ, Ferrara, N, Folkman J. Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. *Growth Factors*. 4, 52-59, 1990.
15. Phillips, HS, Hains J, Leung DW, Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. *Endocrinology*. 127, 965-967, 1990.
16. Ferrara, N, Clapp, C, Weiner, RI. The 16K fragment of prolactin specifically inhibits basal or FGF stimulated growth of capillary endothelial cells. *Endocrinology*. 129, 896-900, 1991.
17. Ferrara, N, Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. *Growth Factors*. 5, 141-148, 1991.
18. Pepper, MS, Ferrara, N, Orci, L, Montesano, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. *Biochem. Biophys. Res. Commun.* 181, 902-906, 1991.
19. Houck, KA, Ferrara, N, Winer, J, Cachianes, G, Leung, DW. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol. Endocrinol.* 5, 1806-1814, 1991.
20. Jakeman LB, Winer, J, Bennett, GL, Altar CA, Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. *J. Clin. Invest.* 89, 244-253, 1992.

21. Ferrara, N, Winer, J, Henzel, WJ. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: Identification as leukemia inhibitory factor. *Proc. Natl. Acad. Sci. USA*. 89, 698-702, 1992.
22. de Vries, C, Escobedo, JA, Ueno, H, Houck, K, Ferrara, N, Williams, LT. The *fms*-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science*. 255, 989-991 1992.
23. Ravindranath, N, Little-Ihrig, L, Phillips, HS, Ferrara, N, Zeleznick, AJ. Vascular endothelial growth factor mRNA expression in the primate ovary. *Endocrinology*. 131, 254-260, 1992.
24. Kim, KJ, Li, B, Houck, K, Winer, J, Ferrara, N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. *Growth Factors*. 7, 53-64, 1992.
25. Unemori, E, Ferrara, N, Bauer, E, Amento, E. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. *J. Cell. Physiol*. 153, 557-562, 1992.
26. Pepper, MS, Ferrara, N, Montesano, R, Orci, L. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. *Biochem. Biophys. Res. Commun*. 189, 824-831, 1992.
27. Houck, K, Leung, DW, Rowland, AM, Winer, J, Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. *J. Biol. Chem*. 267, 26031-26037, 1992.
28. Ferrara, N, Winer, J, Burton, T, Rowland, A, Phillips, HS, Terrell, T, Keller, G-A, Levinson, AD. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. *J. Clin. Invest*. 91, 160-170, 1993.
29. Kim, KJ, Li, B, Winer, J, Armanini, M, Gillett, N, Phillips, HS, Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature*. 362, 841-844, 1993.
30. Jakeman, LB, Armanini, M, Phillips HS, Ferrara, N. Developmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. *Endocrinology*. 133, 848-859, 1993.
31. Quinn, TP, Peters, KG, deVries, C, Ferrara, N, Williams, LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. *Proc. Natl. Acad. Sci. USA*. 90, 7533-7537, 1993.
32. Phillips, HS, Armanini, M, Stavrou, D, Ferrara, N, Westphal, M. Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis. *Int. J. Oncol*. 2, 913-919, 1993.

33. Park, JE, Keller, G-A, Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. *Mol. Biol. Cell.* 4, 1317-1326, 1993.
34. Gillett, N, Lowe, D, Lu, L., Chan, C., Ferrara, N. Leukemia inhibitory factor expression in human carotid plaques: possible mechanisms for inhibition of large vessel endothelial regrowth. *Growth Factors.* 9, 301-305, 1993.
35. Takeshita, S, Zheng, LP, Brogi, E, Kearney, M, Pu, L-Q, Bunting, S, Ferrara, N, Symes, J, Isner, JM. Therapeutic angiogenesis. A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. *J. Clin. Invest.* 93, 662-670, 1994.
36. Pepper, MS, Wasi, S, Ferrara, N, Orci, L, Montesano, R. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. *Exp. Cell Res.* 210, 298-305, 1994.
37. Pertovaara, L, Kaipainen, A, Mustonen, T, Orpava, A, Ferrara, N, Saksela, O, Alitalo, K. Vascular endothelial growth factor is induced in response to transforming growth factor- β in fibroblastic and epithelial cells. *J. Biol. Chem.* 269, 6271-6274, 1994.
38. Koch, AE, Harlow, L, Haines, GK, Amento, EP, Unemori, EN, Wong, W-L, Pope, RM, Ferrara, N. Vascular endothelial growth factor: A cytokine modulating endothelial function in rheumatoid arthritis. *J. Immunol.* 152, 4149-4156, 1994.
39. Shifren, JL, Doldi, N, Ferrara, N, Mesiano, S, Jaffe, RB. In the human fetus, vascular endothelial growth factor (VEGF) is expressed in epithelial cells and myocytes, but not vascular endothelium: Implications for mode of action. *J. Clin. Endocrinol. Metab.* 79, 316-322, 1994.
40. Charnock-Jones, DS, Sharkey, AM, Boocock, CA, Ahmed, A, Plevin, R, Ferrara, N, Smith, SK. Localization and activation of the receptors for vascular endothelial growth factor on human trophoblast and choriocarcinoma cells. *Biol. Reproduct.* 51, 524-530, 1994.
41. Park, JE, Chen, H, Winer, J, Houck, KA, Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. *J. Biol. Chem.* 269, 25646-25654, 1994.
42. Bauters, C, Asahara, T, Zheng, LP, Takeshita, S, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Physiologic assessment of augmented vascularity induced by VEGF in a rabbit ischemic hindlimb model. *Am. J. Physiol.* 267, H1263-H1271, 1994.
43. Aiello, LP, Avery, R, Arrigg, R, Keyt, B, Jampel, H, Shah, S, Pasquale, L, Thieme, H, Iwamoto, M, Park, JE., Nguyen, H, Aiello, LM, Ferrara, N, King, GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N. Engl. J. Med.* 331, 1480-1487, 1994.
44. Takeshita, S, Pu, L-Q, Stein, LA, Sniderman, AD, Bunting, S, Ferrara, N, Isner, JM, Symes, JF. Intramuscular administration of vascular endothelial growth factor induces

- dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. *Circulation*. 90, II228-234, 1994.
45. Shima, DT, Adamis, AP, Yeo, K-T, Yeo, T-K, Allende, Ferrara, N, Folkman, J, D'Amore, PA. Hypoxic induction of vascular endothelial cell growth factors in the retina: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. *Mol. Med.* 2, 64-71, 1995.
 46. Bauters, C, Asahara, T, Zheng, LP, Takeshita, S, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Recovery of disturbed endothelium-dependent flow in collateral-perfused rabbit ischemic hindlimb following administration of VEGF. *Circulation*. 91, 2793-2801, 1995.
 47. Pepper, MS, Ferrara, N, Orci, L, Montesano, R. Leukemia inhibitory factor (LIF) is a potent inhibitor of in vitro angiogenesis. *J. Cell Sci.* 108, 73-83, 1995.
 48. Thieme, H, Aiello, LP, Ferrara, N, King, GL. Comparative analysis of VEGF receptors on retinal and aortic endothelial cells. *Diabetes*. 44, 98-103, 1995.
 49. Bauters, C, Asahara, T, Zheng, LP, Takeshita, S, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Site-specific therapeutic angiogenesis following systemic administration of vascular endothelial growth factor. *J. Vasc. Surg.* 21, 314-325, 1995.
 50. Warren, RS, Yuan, H, Matli, MR, Gillett, N, Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. *J. Clin. Invest.* 95, 1789-1797, 1995.
 51. Mandriota, S, Montesano, R, Orci, L, Seghezzi, G, Vassalli, J-D, Ferrara, N, Mignatti, P, Pepper, MS. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. *J. Biol. Chem.* 270, 9709-9716, 1995.
 52. Asahara, T, Bauters, C, Pastore, C, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Local delivery of vascular endothelial growth factor accelerates re-endothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. *Circulation*. 91, 2802-2809, 1995.
 53. Aiello, LP, Pierce, EA, Foley, ED, Takagi, H, Riddle, L, Chen, H, Ferrara, N, King, GL, Smith, LE. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. *Proc. Natl. Acad. Sci. USA*. 92, 10457-10461, 1995.
 54. Takeshita, S, Rossow, ST, Kearney, M, Zheng, LP, Bauters, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Time course of increased cellular proliferation in collateral arteries following administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. *Am. J. Pathol.* 147, 1649-1660, 1995.
 55. Asahara, T, Bauters, C, Zhang, LP, Takeshita, S, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Synergistic effects of VEGF and bFGF on angiogenesis in vivo. *Circulation*. 92, 365-371, 1995.

56. Walder, CE, Errett, CJ, Ogez, J, Heinshon, H, Bunting, S, Lindquist, P, Ferrara, N, Thomas, GR. Vascular endothelial growth factor (VEGF) improves blood flow and function in a chronic ischemic hind-limb model. *J. Cardiovasc. Pharmacol.* 27, 91-98, 1996.
57. Walter, DH, Hink, U, Asahara, T, Van Belle, E, Horowitz, J, Tsurumi, Y, Vandlen, R, Heinshon, H, Keyt, B, Ferrara, N, Symes, JF, Isner, JM. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. *Lab. Invest.* 74, 546-556, 1996.
58. Adamis, AP, Shima, DT, Tolentino, M, Gragoudas, E, Ferrara, N, Folkman, J, D'Amore, PA, Miller JW. Inhibition of VEGF prevents ocular neovascularization in a primate. *Arch. Ophthalmol.* 114, 66-71, 1996.
59. Takagi, H, King, GL, Ferrara, N, Aiello, LP. Hypoxia regulates VEGF receptor KDR/Flk-1 gene expression through adenosine A₂ receptors in retinal capillary endothelial cells. *Invest. Ophthalmol. Vis. Sci.* 37, 1311-1321, 1996.
60. Keyt, B, Nguyen, H, Berleau, L, Duarte, C, Park, J, Chen, H, Ferrara, N. Identification of VEGF determinants for binding Flt-1 and KDR receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. *J. Biol. Chem.* 271, 5638-5646, 1996.
61. Yang, R, Thomas, GR, Bunting, S, Ko, A, Keyt, B, Ferrara, N, Ross, J, Jin, H. Effects of VEGF on hemodynamics and cardiac performance. *J. Cardiovasc. Pharmacol.* 27, 838-844, 1996.
62. Keyt, B, Berleau, L, Nguyen, H, Heinshon, H, Chen H, Vandlen, R, Ferrara, N. The carboxyl-terminal domain (111-165) of VEGF is critical for mitogenic potency. *J. Biol. Chem.* 271, 7788-7795, 1996.
63. Ferrara, N, Carver-Moore, K, Chen, H, Dowd, M, Lu, L, O'Shea, S, Powell-Braxton, L, Hillan, KJ, Moore, MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature.* 380, 439-442, 1996.
64. Tolentino, MJ, Miller, JW, Gragoudas, ES, Chatzistefanou, K, Ferrara, N, Adamis, AP. VEGF is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. *Arch. Ophthalmol.* 114, 964-970, 1996.
65. Borgström, P, Hillan, KJ, Sriramaraio, P, Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-VEGF neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicroscopy. *Cancer Res.* 56, 4032-4039, 1996.
66. Davis-Smyth, T, Chen, H, Park, J, Presta, LG, Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. *EMBO J.* 15, 4919-4927, 1996.
67. Shifren, JL, Tseng, JF, Zaloudek, CJ, Ryan, IP, Meng, YG, Ferrara, N, Jaffe, RB, Taylor, RN. Ovarian steroid regulation of VEGF in human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. *J. Clin. Endocrinol. Metab.* 81, 3112-3118, 1996.

68. Takagi, H, King, GL, Robinson, GS, Ferrara, N, Aiello, LP. Hypoxic induction of VEGF is mediated by adenosine through A₂ receptors and elevation of cAMP in retinal pericytes and endothelial cells. *Invest. Ophthalmol. Vis. Sci.* 37, 2165-2176, 1996.
69. Takeshita, S, Weir, Cheng, D, L Zheng, L R, Bauters, C, Symes, J, Ferrara, N, Isner, JM. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. *Biochem. Biophys. Res. Commun.* 227, 628-635, 1996.
70. Takeshita, S, Tsurumi, Y, Couffinhal, T, Asahara, T, Bauters, C, Symes, JF, Ferrara, N, Isner, JM. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. *Lab. Invest.* 75, 487-502, 1996.
71. Warren, RS, Yuan, H, Matli, MR, Ferrara, N, Donner, DB. Induction of vascular endothelial growth factor by insulin like growth factor 1 in colorectal carcinoma. *J. Biol. Chem.* 271. 29483-29488, 1996.
72. Koch, AE, Halloran, NM, Hosaka, S, Shah, MR, Haskell, CJ, Baker, SK, Panos, R, Haines, R, Bennett, G, Pope, RM, Ferrara, N. Hepatocyte growth factor: a cytokine mediating endothelial migration in inflammatory arthritis. *Arthr. Rheum.* 39, 1566-1575, 1996.
73. Christinger, HW, Muller, Y, Berleau, LT, Keyt, BA, Cunningham, B, Ferrara, N, deVos, AM. Crystallization of the receptor-binding domain of VEGF. *Prot: Struct., Funct. Genet.* 26, 353-357, 1996.
74. Yuan, F, Dellian, M, Safabakhsh, N, Ferrara, N, Jain, R. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by anti-VEGF/VPF antibody. *Proc. Natl. Acad. Sci. USA.* 93, 14765-14770, 1996.
75. Tolentino, MJ, Miller, JW, Gragoudas, ES, Jakobiec, FA, Flynn, E, Chatzistefanou, K, Ferrara, N, Adamis, AP. Intravitreal injections of VEGF produce retinal ischemia and microangiopathy in an adult primate. *Ophthalmology.* 11, 1820-1828, 1996.
76. Gerber, HP, Condorelli, F, Park, J, Ferrara, N. Differential transcriptional regulation of the two VEGF receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. *J. Biol. Chem.* 272, 23659-23667, 1997.
77. Presta, LG, Chen, H, O'Connor, SJ, Chisholm, V, Meng, G, Krummen, L, Winkler, M, Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res.* 57, 4593-4599, 1997.
78. Kirshenbaum, A, Wang, J-P, Schiff, JD, Aaronson, SA, Drolller, MJ, Ferrara, N, Holland, JF, Levine, AC. Inhibition of VEGF suppresses the in vivo growth of human prostate tumors. *Urol. Oncol.* 3, 3-10, 1997.
79. Van Belle, E, Rivard, A, Chen, D, Silver, M, Bunting, S, Ferrara, N, Symes, JF, Isner, JM. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. *Circulation.* 96, 2667-2674, 1997.

80. Davis-Smyth, T, Presta, L, Ferrara, N. Mapping the charged residues in the second immunoglobulin-like domain of the VEGF/PlGF receptor Flt-1 required for binding and structural stability. *J. Biol. Chem.* 273, 3216-3222, 1998.
81. Yang, R, Bunting, S, Ko, A, Keyt, B, Modi, N, Zioncheck, T, Ferrara, N, Jin, H. Substantially attenuated hemodynamic response to E.Coli-derived vascular endothelial growth factor given by intravenous infusion compared to bolus administration. *J. Pharmacol. Exp. Ther.* 284, 103-110, 1998.
82. Borgström, P, Hillan, KJ, Sriramaraio, P, Ferrara, N. Anti-vascular endothelial growth factor antibody inhibits angiogenesis and growth of human prostatic cancer in vivo. *Prostate.* 35, 1-10, 1998.
83. Ferrara, N., Chen, H, Davis-Smyth, T, Nguyen, N, Gerber, H, Peers, D, Chisholm, V, Hillan, KJ, Schwall, R. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. *Nature Med.* 4, 336-340, 1998.
84. Shifren, JL, Mesiano, S, Taylor, RN, Ferrara, N, Jaffer RB. Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cells. *J. Clin. Endocrinol. Metab.* 83, 1342-1347, 1998.
85. Gerber, HP, Dixit, V, Ferrara, N. Vascular endothelial growth factor (VEGF) induces expression of the antiapoptotic proteins Bcl-2 and A-1 in endothelial cells. *J. Biol. Chem.* 273, 13313-13316, 1998.
86. Pham, CD, Roberts, TPL, van Bruggen, N, Melnyk, O, Mann, J, Ferrara, N, Cohen, RL, Brasch, RC. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. *Cancer Invest.* 16, 225-230, 1998.
87. Giraudo, E, Primo, L, Audero, E, Gerber, HP, Koolwijk, P, Klagsbrun, M, Ferrara, N, Bussolino, F. Tumor necrosis factor- α regulates expression of vascular endothelial growth factor receptor-2 and its co-receptor neuropilin-1 in human vascular endothelial cells. *J. Biol. Chem.* 273, 22128-22135, 1998.
88. Shen, B-Q, Lee, D, Gerber, HP, Keyt, BA, Ferrara, N, Zioncheck, TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor (VEGF) in vitro. *J. Biol. Chem.* 273, 29979-29986, 1998.
89. Gerber, HP, McMurtrey, A, Kowalski, J, Yan, M, Keyt, BA, Dixit, V, Ferrara, N. Vascular endothelial growth factor inhibits apoptosis by the PI3 kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. *J. Biol. Chem.* 273, 30336-30343, 1998.
90. Mesiano, S, Ferrara, N, Jaffe, RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. *Am. J. Pathol.* 15, 1249-1256, 1998.
91. Shi, Y-P, Ferrara, N. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking VEGF. *Biochem. Biophys. Res. Commun.* 254, 480-483, 1999.

92. Gerber, HP, Hillan, KJ, Ryan, AM, Kowalski, J, Keller, G-A, Rangell, L, Wright, BD, Radtke, F, Aguet, M, Ferrara, N. VEGF is required for growth and survival in neonatal mice. *Development*. 126, 1149-1159, 1999.
93. Mordenti, J, Thomsen, K, Licko, V, Chen, H, Meng, G, Ferrara, N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. *Toxicol. Pathol.* 27, 14-21, 1999.
94. Bayko, L, Rak, J, Man, S, Bicknell, R, Ferrara, N, Kerbel, RS. Termination of the dormant phenotype of early stage primary human cutaneous melanoma by overexpression of vascular endothelial growth factor. *Angiogenesis*. 2, 203-217, 1999.
95. Lichtembeld, H, Ferrara, N, Jain, RK, Munn, I. Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. *Microvasc. Res.* 57, 357-362, 1999.
96. Gerber, HP, Vu, TH, Ryan, AM, Kowalski, J, Werb, Z, Ferrara, N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. *Nature Med.* 5, 623-628, 1999.
97. Mordenti, J, Cuthbertson, A, Ferrara, N, Tomsen, K, Berleau, L, Valverde, C, Licko, V, Ryan, A. Intraocular distribution, pharmacokinetics and safety of an intact antibody and an Fab fragment following intravitreal administration in Rhesus monkeys of ¹²⁵I-labeled test material. *Toxicol. Pathol.* 5, 536-544, 1999.
98. van Bruggen, N, Thibodeaux, H, Palmer, JT, Cairns, B, Tumas, D, Williams, S-P, van Lookeren Campagne, M, Ferrara, N. VEGF antagonism reduces cerebral edema formation and tissue damage following ischemic-reperfusion injury in the mouse brain. *J. Clin. Invest.* 104, 1613-1620, 1999.
99. Borgström, P, Hillan, KJ, Sriramaraio, P, Ferrara, N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. *Anticancer Res.* 19, 4303-4314, 1999.
100. Haigh, JJ, Gerber, HP, Ferrara, N, Wagner, EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. *Development*. 127, 1445-1453, 2000.
101. Hemmlinger, G, Endo, M, Hlatcy, L, Ferrara, N, Jain, RK. Dynamics of oxygen gradient-induced angiogenesis via endothelial VEGF. *Nature*. 405, 139-141, 2000.
102. Gille, H, Kowalski, J, Yu, L, Chen, H, Pisabarro, MT, Davis-Smyth, T, Ferrara, N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3'-kinase activation and endothelial cell migration. *EMBO J.* 19, 4064-4073, 2000.
103. Drake, CJ, LaRue, A, Ferrara, N, Little, CD. VEGF regulates cell behavior during vasculogenesis. *Dev. Biol.* 224, 178-188, 2000.
104. Lee, GC, Hejin, M, di Tomaso, E, Ancukiewicz, M, Kolke, C, Griffon-Etienne, G, Park, KR, Ferrara, N, Jain, RK, Suit, HD, Boucher, Y,. Anti-VEGF treatment augments tumor

- radiation response under normoxic or hypoxic conditions. *Cancer Res.* 60, 5565-5570, 2000.
105. Gossman, A, Helbich, TH, Mesiano, S, Shames, DM, Wendland, MF, Roberts, TP, Ferrara, N, Jaffe, RB, Brasch, RC. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. *Am. J. Obstet. Gynecol.* 183, 956-963, 2000.
 106. Gerber, HP, Kowalski, J, Sherman, D, Eberhard, D, Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth requires both tumor and host VEGF blockade. *Cancer Res.* 60, 6253-6258, 2000.
 107. Gille, H, Kowalski, J, Li, B, LeCouter, J, Moffat, B, Zioncheck, T, Pelletier, N, Ferrara, N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific VEGF mutants. *J. Biol. Chem.* 276, 3222-3230, 2001.
 108. Xin, X, Yang, S, Ingle, G, Kowalski, J, Schwall, R, Ferrara, N, Gerritsen, ME. HGF enhances VEGF-induced angiogenesis, in vitro and in vivo. *Am. J. Pathol.* 158, 1111-1120, 2001.
 109. Giordano, F, Gerber, HP, Williams, S-P, van Bruggen, N, Bunting, S, Ruiz-Lozano, P, Gu, Y, Nath, AK, Huang, Y, Hickey, R, Dalton, N, Peterson, KL, Ross, J, Chien, KR, Ferrara, N. A cardiac myocyte VEGF pathway is required to maintain cardiac function. *Proc. Natl. Acad. Sci. USA.* 98, 5780-5785, 2001.
 110. Hu, Y-L, Tee, M-K, Goetzl, EJ, Mills, GB, Ferrara, N, Jaffe, RB. Induction of VEGF expression by lysophosphatidic acid (LPA) in neoplastic human ovarian epithelial cells. *J. Natl. Cancer Inst.* 93, 762-767, 2001.
 111. LeCouter, J, Kowalski, J, Foster, Z, Rangell, L, Keller, G-A, Hass, P, DeGuzman, L, Frantz, G, Peale, F, Gurney, A, Hillan, KJ, Ferrara, N. Identification of an angiogenic mitogen selective for endocrine gland endothelium. *Nature.* 412, 877-884, 2001.
 112. Zheng, M, Deshpande, M, Ferrara, N, Rouse, BT. Contribution of VEGF in the neovascularization process during the pathogenesis of herpetic stromal keratitis. *J. Virol.* 75, 9828-9835, 2001.
 113. Williams, S-P, Gerber, HP, Giordano, F, Peale, F, Bernstein, L, Bunting, S, Chien, KR, Ferrara, N, van Bruggen, N. Dobutamine-stress cine MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice. *J. MRI.* 14, 374-382, 2001.
 114. Clyman, RI, Seider, SR, Kajino, H, Roman, C, Koch, C, Ferrara, N, Waleh, N, Mauray, F, Chen, YQ, Quinn, T. VEGF regulates permanent anatomic closure of the ductus arteriosus. *Am. J. Physiol.* 282, R199-R206, 2002.
 115. Lin R, LeCouter, J, Kowalski, J, Ferrara, N. Characterization of EG-VEGF signaling in adrenal cortex capillary endothelial cells. *J. Biol. Chem.* 277, 8724-8729, 2002.
 116. Camenish, G., Pisabarro, MT, Sherman, D, Kowalski, J, Nagel, M, Hass, Xie, M-H, Gurney, A, Bodary, S, Liang, XH, Clark, K, Beresini, M, Ferrara, N, Gerber, HP.

- ANGPTL3 stimulates endothelial cell adhesion and migration via integrin $\alpha v \beta 3$ and induces blood vessel formation in vivo. *J. Biol. Chem.* 277, 17281-17290, 2002.
117. Inoue, M, Hager, JH, Ferrara, N, Gerber, HP, Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switch and pancreatic β -cell carcinogenesis. *Cancer Cell.* 1, 193-202, 2002.
 118. Gerber, HP, Malik, A, Solar, G, Sherman, D, Liang, XH, Meng, G, Hong, K, Marsters, JC, Ferrara, N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature.* 417, 954-958, 2002.
 119. Street, J, Bao, M, deGuzman, L, Bunting, S, Peale, F, Ferrara, N, Steinmetz, H, Hoeffel, J, Cleland, J, Daugherty, A, vanBruggen, N, Redmond, HP, Richard, AD, Carano, R, Filvaroff, E. VEGF stimulates bone repair by promoting angiogenesis and bone turnover. *Proc. Natl. Acad. Sci. USA.* 99, 9656-9661, 2002.
 120. Hu, L, Hofmann, J, Zaloudek, C, Ferrara, N, Hamilton, T, Jaffe, RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. *Am. J. Pathol.* 161, 1917-1924, 2002.
 121. LeCouter, J, Moritz, DR, Li, B, Phillips, GL, Liang, XH, Gerber, HP, Hillan, KJ, Ferrara, N. Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1. *Science.* 299, 890-893, 2003.
 122. LeCouter, J, Lin, R, Frantz, G, Tejada, M, Peale, F, Hillan, KJ, Ferrara, N. The EG-VEGF homologue Bv8 promotes angiogenesis in the testis. Localization of Bv8 receptors to endothelial cells. *Proc. Natl. Acad. Sci. USA.* 100, 2685-2690, 2003.
 123. Eremina V, Sood, M, Haigh, J, Nagy, A, Lajoie, G, Ferrara, N, Gerber, HP, Kikkawa, Y, Miner, JH, Quaggin, SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. *J. Clin. Invest.* 111, 707-716, 2003.
 124. Cramer, T, Yamanishi, Y, Firestein, G, Clausen, BE, Forster, I, Pawlinski, R, Mackman, N, Haase, V, Jenisch, R, Gerber, HP, Ferrara, N, Johnson, RS. HIF-1 α is essential for myeloid cell-mediated inflammation. *Cell.* 112, 645-657, 2003.
 125. LeCouter, J, Lin, R, Frantz, G, Zhang, Z, Hillan KJ, Ferrara, N. Mouse EG-VEGF: A distinct expression pattern from its human orthologue suggests different roles as a regulator of organ-specific angiogenesis. *Endocrinology.* 144, 2606-2616, 2003.
 126. Ferrara, N, Frantz, G, LeCouter, J, Dillard-Telm, L, Pham, T, Giordano, T, Peale F. Differential expression of the angiogenic factor genes, EG-VEGF and VEGF, in normal and polycystic human ovaries. *Am. J. Pathol.* 162, 1881-1893, 2003.
 127. Lammert, E, Gu, G, McLaughlin, M, Brown, D, Brekken, R, Gerber, HP, Ferrara, N, Melton, D. Role of VEGF-A in vascularization of pancreatic islets. *Curr. Biol.* 13, 1070-1074, 2003.
 128. Nicoletti, VG, Nicoletti, R, Ferrara, N, Meli, G, Reibaldi, M, Reibaldi, A. Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). *Exp. Clin. Endocrinol. Diab.* 111, 209-214, 2003.

129. Haigh, JJ, Gerhardt, H, Morelli, P, Haigh, K, Tsien, J, Damert, A, Miquerol, L, Muhlner, L, Klein, R, Ferrara, N, Wagner, EF, Betscholtz, C, Nagy, A. Cortical and retinal defects caused by dosage dependent reductions in VEGF-A paracrine signaling. *Dev. Biol.* 262, 225-241, 2003.
130. Blouw, B, Song, H, Tihan, T, Bosze, J, Ferrara, N, Gerber, HP, Johnson, RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. *Cancer Cell*, 4, 133-146, 2003.
131. Lissbrant, IF, Hamamrstein, P, Lissbrant, E, Ferrara, N, Rodolfsson, SH, Bergh, A. Neutralizing VEGF bioactivity with a soluble chimeric VEGF receptor protein Flt (1-3) IgG inhibits testosterone induced prostate growth in castrated mice. *Prostate*, 58, 57-65, 2004.
132. Raab, S, Beck, H, Gaumann, A, Yüce, A, Gerber, HP, Plate, KH, Klein, R, Hammes, HP, Ferrara, N, Breier, G. VEGF is essential for brain angiogenesis and development. *Thromb. Hem.* 91, 595-605, 2004.
133. Tang, K, Breen, EC, Gerber, HP, Ferrara, N, Wagner, P. Capillary regression in VEGF deficient skeletal muscle. *Physiol. Genom.* 18, 63-69, 2004.
134. Zelzer, E, Mamluk, R, Ferrara, N, Johnson, RJ, Schipani, E, Olsen, BR. VEGF is necessary for chondrocyte survival during bone development. *Development*. 131, 2161-2171, 2004.
135. Hesser, B, Liang, XH, Ruchatz, A, Sherman, D, Camenish, G, Yang, S, Bush, J, Lin, N, Sjhov, P, Lewin, D, Scheller, R, Ferrara, N, Gerber, HP. Down syndrome critical region protein1 (DSCR1) interferes with NFAT activity and attenuates expression of inflammatory marker genes on activated endothelial cells. *Blood*. 104, 149-158, 2004.
136. Hurwitz, H, Fehrenbacher, L, Novotny, W, Cartwright, T, Hainsworth, H, Helm, W, Berlin, J, Baron, A, Griffing, S, Holmgren, E, Ferrara, N, Fyfe, G, Rogers, B, Ross, R, Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N. Engl. J. Med.* 350, 2335-2342, 2004.
137. Dalrup-Link, HE, Okuhata, Y, Wolfe, A, Srivastav, S, Oie, S, Ferrara, N, Cohen, RL, Shames, DM, Brasch, RC. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. *Microcirculation* 11, 387-396, 2004.
138. Samson, M, Peale, F, Frantz, G, Rioux-Leclercq, N, Rajpert-De Meyts, E, Ferrara, N. Human EG-VEGF: Expression early in development and in Leydig cell tumors suggest roles in normal and pathological testis angiogenesis. *J. Clin. Endocrinol. Metab.* 89, 4078-4088, 2004.
139. Dong, J, Grunstein, J, Tejada, M, Peale, F, Frantz, G, Liang, W-C, Bai, W, Yu, L, Kowalski, J, Liang, X, Fuh, G, Gerber, HP, Ferrara, N. VEGF-null cells require PDGFR- α signaling-mediated stromal fibroblast recruitment for tumorigenesis. *EMBO J.* 23, 2800-2810, 2004.

140. Khurana, R, Zhuang, Z, Bhardwaj, S, Murakami, M, De Muinck, E, Yla-Herttuala, S, Ferrara, N, F Martin, J, Zachary, I, Simons, M. Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia. **Circulation**. 110, 2436-2443, 2004.
141. LeCouter, J, Zlot, C, Tejada, M, Peale, F, Ferrara, N. Bv8 and EG-VEGF stimulate hematopoiesis and hematopoietic cell mobilization. **Proc. Natl. Acad. Sci. USA**. 101, 16813-16818, 2004.
142. Tang, N, Wang, L, Esko, J, Giordano, FJ, Gerber, HP, Ferrara, N, Johnson, RS. Solid tumor angiogenesis requires an endothelial cell hypoxic response. **Cancer Cell**. 6, 485-495, 2004.
143. Mukoyama, YS, Gerber, HP, Ferrara, N, Gu, C, Anderson, DJ. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin-1-mediated positive feedback. **Development**. 132, 941-952, 2005.
144. Zhao, L, Wang, K, Ferrara, N, Werb, Z, Vu, TH. Vascular Endothelial Growth Factor coordinates proper development of lung epithelium and vasculature **Mech. Dev**. 122, 877-886, 2005.
145. Marnaros AG, Fan, J, Yokoyama, Y, Gerber, HP, Ferrara, N, Crouch, RK, Olsen BR. VEGF expression in the retinal pigment epithelium is essential for choroid development and visual function. **Am. J Path.** 167:1451-1459, 2005.
146. Malik, A, Fuh, G,, Liang, WC, Lowman, H, Kowalski,J, Meng, G, Hillan, K, Peale, F, Ferrara, N, Gerber, HP. Redundant role of PlGF and VEGF during postnatal development. **Blood**. 107, 550-557, 2006.
147. Liang, W-I, Wu, X, Peale, FV, Meng, G, Gutierrez, J, Lee, CV, Malik, A, Gerber HP, Ferrara, N, Fuh, G. cross-species VEGF-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. **J. Biol. Chem**. 281, 951-956, 2006.
148. Nikolova, G, Jabs, N, Konstantinova, I, Domogastkaya, A, Tryggvason, K, Sorokin, L, Fassler, R, Gu, G, Gerber, HP, Ferrara, N, Melton, DA, Lammert, E. The vascular basement menbrane; a niche for insulin gene expression and Beta cell proliferation. **Dev. Cell**. 10, 397-405, 2006.
149. Tejada, M, Yu, L, Dong, J, Jung, K, Meng, G, Peale, FV, Frantz, G, Bai, W, Liang, XU, Gerber, HP, Ferrara, N. Tumor-directed paracrine PDGFR-alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. **Clin. Cancer Res**. 12, 2676-2688, 2006.
150. Eremina, V, Cui, S, Gerber, HP, Ferrara, N, Haigh, J, Nagy, A, Ema, M, Rossant, J, Jothy, S, Miner, JH, Quaggin, SE. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. **J. Am Soc. Nephrol**. 17, 724-735, 2006.
151. Hu, L, Ferrara, N, Jaffe, RB. Paracrine VEGF/VE-Cadherin Action on Ovarian Cancer Permeability. **Exp. Med. Biol**. 231, 1646-1652, 2006.

152. Ambati, BK, Nozaki, M, Singh, N, Takeda, A, Richter, E, Albuquerque, R, Suthar, T, Sakurai, E, Caldwell, R, Ogura, Y, Mahasrethi, P, Orecchia, A, Samuelson, DA, Agnew, DW, St Leger, J, Ikeda, S, Leiper, LJ, Collinson, M, Bogdanovich, S, Khurana, T, Shibuya, M, Baldwin, ME, Ferrara, N, Gerber, HP, De Falco, S, Witta, J, Baffi, J, Raisler, BJ, Ambati, J. Corneal avascularity is due to soluble VEGF Receptor 1. *Nature*. 443, 993-907, 2006.
153. Gerber, HP, Wu, X, Yu, L, Fuh, G, Weissman, C, Liang, X-H, Olson, C, Damico, L, Xie, D, Meng, G, Corpuz, R, Li, B, Hall, L, Rangell, L, Ferrando, R, Gutierrez, J, Lowman, H, Peale, F Ferrara, N. Mice expressing a humanized form of VEGF-A may provide insights into safety and efficacy of anti-VEGF antibodies. *Proc. Natl. Acad. Sci. USA*. 104, 3478-3483, 2007.
154. Liang, W-C, Dennis, MS, Stawicki, S, Chanterey, I, Pan, Q, Eigenbrot, C, Yin, J, Koch, A, Wu, X, Ferrara, N, Bagri, A, Tessier-Lavigne, M, Watts, R, Wu, Y. Functional Blocking Antibodies to Neuropilin-1 Generated from a Designed Human Synthetic Antibody Phage Library. *J. Mol. Biol.* 366, 815-829, 2007.
155. Iwashita, N, Choi, JB, Uchida, T, Kosuke Azuma, T, Ogihara, T, Tanaka, Y, Ferrara, N, Gerber, HP, Kawamori, R, Inoue, M, Watada, H. Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. *Diabetologia*. 50, 380-389, 2007.
156. Korsisaari, N, Kasman, I, Forrest, W, Pal, N, Fuh, G, Peale, F, Smits, R, Ferrara, N. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of $Apc^{+/min}$ mice. *Proc. Natl. Acad. Sci. USA*. 104, 10625-10630, 2007.
157. Yamamoto, H, Yun, EY, Gerber, HP, Ferrara, N, Whitsett, JA Vu, TH. Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. *Dev. Biol.* 308, 44-53, 2007.
158. Shojaei, F, Wu, X, Baldwin, ME, Zhong, C, Malik, A, Shanz, S, Fuh, G, Gerber, HP, Ferrara, N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. *Nature Biotechnol.* 25, 911-920, 2007.
159. Lee, S, Chen, TT, Jordan, M, Murdock, J, Desai, S, Ferrara, N, Nagy, A, Roos, KP, Iruela-Arispe, L. Autocrine VEGF signaling is required for vascular homeostasis. *Cell*. 130, 691-703, 2007.
160. Shojaei, F, Wu, X, Zhong, C, Yu, L, Liang, XH, Yao, J, Blanchard, D Peale, F, Bais, C, Van Bruggen, N, Ho, C, Ross, J, Tan, M, Carano R, Meng, YG, Ferrara, N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. *Nature*. 450, 825-831, 2007.
161. Korsisaari, N, Ross, J, Wu, X, Pal, N, Kowanzetz, M, Hall, L, Eastham-Anderson, J, Forrest, W, Van Bruggen, N, Peale, FV, Ferrara, N. Blocking VEGF-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of Multiple Endocrine Neoplasia Type 1. *Clin. Cancer Res.* 14, 249-258, 2008.
162. Yu, L, Wu, X, Cheng, Z, Lee, C, LeCouter, J, Campa, C, Fuh, G, Lowman, H, Ferrara, N. Interaction between bevacizumab and mouse VEGF-A: A reassessment. *Invest. Ophthalmol. Vis. Sci.* 49, 522-527, 2008.
163. Shojaei, F, Singh, M, Cox, JD, Ferrara, N. Role of Bv8 in neutrophil-dependent

- angiogenesis in a transgenic model of cancer progression. *Proc. Natl. Acad. Sci. USA*. 105, 2640-2645, 2008.
164. Campa, C, Kasman, I, Ye, W, Lee, W, Fuh, G, Ferrara, N. Effects of an anti-VEGF monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. *Invest. Ophthalmol. Vis. Sci*. 49, 1178-1183, 2008.
 165. Eremina, V, Jefferson, A, Kowalewska, J, Hochster, H, Haas, M, Weisstuch, J, Richardson, C, Kopp, JB, Kabir, G, Backx, , Gerber, HP, Ferrara, N, Barisoni, L, Alpers, CE, Quaggin, SE. VEGF inhibition leads to renal thrombotic microangiopathy. *N. Engl. J. Med*. 358, 1129-1136, 2008.
 166. Berry, LR, Barck, KH, Go, MA, Ross, J, Wu, X, Williams, SP, Gogineni, A, Van Bruggen, N, Fuh, G, Peale, F, Ferrara, N, Ross, S, Schwall, RS, Carano, R. Quantification of viable tumor microvascular characteristics by multispectral analysis. *Magn. Reson. Med*. 60, 64-72, 2008.
 167. Jebb, N, Franklin, I, Brenner, MB, Gromada, J, Ferrara, N, Wollheim, CB, Lammert, E. Reduced insulin secretion and content in VEGF-A deficient mouse pancreatic islets. *Exp. Clin. Endocrinol. Diabetes*. 116 Suppl. 1, S46-49, 2008.
 168. Garcia, CM, Shui, YB, Kamath, M, Devillar, J, Johnson, RS, Gerber, HP, Ferrara, N, Robinson, ML, Beebe, DC. The function of VEGF-A in lens development: Formation of the hyaloid capillary network and protection against transient nuclear cataracts. *Exp. Eye Res*. 88, 270-276, 2009.
 169. Crawford, Y, Kasman, IM, Yu, L, Zhong, C, Wu, X, Modrusan, Z, Kaminker, J, Ferrara, N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. *Cancer Cell*. 15, 21-34, 2009.
 170. Eshar-Oren, I, Viukov, SV, Salameh, S, Krief, S, Oh, CD, Akiyama, H, Gerber, HP, Ferrara, N, Zelzer, E. The forming limb skeleton serves as a signaling cart for limb vasculature patterning via regulation of vegf. *Development*. 136, 1263-1272, 2009.
 171. Zhong, C, Qu, X, Tan, M, Meng, YG, Ferrara, N. Characterization and regulation of Bv8 in human blood cells. *Clin. Cancer Res*. 15, 2675-2684, 2009.
 172. Shojaei, F, Wu, X, Qu, X, Tan, M, Meng, G, Ferrara, N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF treatment in mouse models. *Proc. Natl. Acad. Sci. USA*. 106, 6742-6747, 2009.
 173. Chappel, JC, Taylor, SM, Ferrara, N, Bautch, VL. Local guidance of emerging vessel sprouts requires soluble Flt-1 (VEGFR-1). *Dev. Cell*. 17, 377-386, 2009.
 174. O'Connor JPB, Carano, RA, Clamp, AR, Ross, J, Ho, CK, Jackson, A, Parker, GJM, Rose, CJ, Peale, FV, Friesenhahn, M, Mitchell CL, Watson, Y, Roberts, C, Hope, L, Cheung, S, Reslan, HB, Go, MA, Pacheco, G, Wu, X, Cao, T, Ross, S, Buonaccorsi, GA, Davies K, Hasan, J, Thornton, P, del Puerto, O, Ferrara, N, van Bruggen, N, Jayson, GC. Quantifying the anti-vascular effects of monoclonal antibodies to VEGF: insights from imaging. *Clin. Cancer Res*. 15, 6674-6682, 2009.
 175. Strillic, B, Kucera, T, Eglinger, J, Hughes, MR, McNagny, KM, Tsukita, S, Lampugnani, MG, Dejana, E, Ferrara, N, Lammert, E. The molecular basis of lumen formation in the dorsal aorta of mice. *Dev. Cell*. 17, 505-515, 2009.
 176. Lichtenberger, BM, Tan, PK, Niederleithner, H, Ferrara, N, Petzelbauer P, Sibilio, M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. *Cell*. 140, 268-279, 2010.

177. Liu, BY, Soloviev, I, Chang, P, Lee, J, Huang, XD, Zhong, C, Ferrara, N, Polakis, P, Sakanaka, C. Stromal derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth by recruiting bone marrow-derived cells. *PloS One*. 5, e8611, 2010.
178. Ortega, N, Wang, K, Ferrara, N, Werb, Z, Vu, T. Complementary interplay between VEGF, MMP9 and osteoclast function drives endochondral bone formation. *Dis. Mod. Mechan.* 3, 224-235, 2010.
179. Mura, M, Binnie, M, Han, B, Li, C, Andrade, CF, Shiozaki, A, Zhang, Y, Ferrara, N, Hwang, D, Waddell, TK, Keshavjee, S, Liu, M. Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. *Am. J Pathol.* 176, 1564-1576, 2010.
180. Bais, C, Wu, X, Yao, J, Crawford, Y, McCutcheon, K, Tan, C, Yang, S, Vernes, JM, Easthan-Anderson, J, Haughney, P, Kowanetz, M, Hagenbeck T, Kasman, I, Meng, G, Hongo, JA, Stephan, JP, Shibuya, M, Ferrara, N. PlGF blockade does not inhibit angiogenesis during primary tumor growth. *Cell*. 141, 166-177, 2010.
181. Yeung, A, Wu, X, Reyes, AE, Vernes, J-M, Lien, S, Lowe, J, Maia, M, Forrest, W, Meng, G, Damico, LA, Ferrara, N, Lowman, HB. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. *Cancer Res*. 70, 3269-3277, 2010.
182. Scott A, Powner, MB, Gandhi, P, Clarkin, C, Gutmann, DH, Johnson, RS, Ferrara, N, Fruttiger, M. Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. *PloS One*. 5, e11863, 2010.
183. Drogat, B, Kalucka, J, Hammad, H, Goossens, S, FM, Ghahremani, Bartunkova, S, Haigh, K, Deswarte, K, Nyabi, O, Naessens, M, Ferrara, N, Klingmüller, U, Lambrecht, B, Nagy, A. VEGF regulates embryonic erythroid development through GATA1 modulation. *Blood*. 116, 2141-2151, 2010.
184. Kowanetz, M, Wu, X, Qu, X, Tan, M, Hagenbeeck, T, Ross, J, Korsisaari, N, Cao, T, Bou-Reslan, H, Kallop, D, Weimer, R, Ludlam, MC, Kaminker, JS, Modrusan, Z., van Bruggen, N, Peale, FV, Carano, R, Meng, YG, Ferrara, N. G-CSF promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. *Proc. Natl. Acad. Sci. USA*. 104, 21248-21255, 2010.
185. Yu, L, Liang, XH, Ferrara, N. Comparing protein VEGF inhibitors: *In vitro* biological studies. *Biochem. Biophys. Res. Commun.* 408, 276-281, 2011.
186. Stefater, JA, Lewkowich, I, Rao, S, Ajima, R, Mariggi, G, Wills-Karp, M, Pollard, J, Yamaguchi, T, McMahon, AP, Ferrara, N, Gerhardt, H, Lang, RA. Microglial Wnt ligands suppress retinal angiogenesis via activation of the VEGF inhibitor Flt1. *Nature*. 474, 511-515, 2011.
187. Yao, J, Wu, X, Zhuang, G, Kasman, I, Vogt, T, Phan, V, Shibuya, M, Ferrara, N, Bais, C. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. *Proc. Natl. Acad. Sci. USA*. 108, 11590-11595, 2011.
188. Milgrom-Hoffman, M, Harrelson, Z, Ferrara, N, Zelzer, E, Evans, SM, Tzahor, E. The heart endocardium is derived from heart endothelial progenitors. *Development*. 138, 4777-4787, 2011.

189. Qu, X, Zhuang, G, Yu, L, Meng, G, Ferrara, N. Induction of Bv8 expression by granulocyte-colony stimulating factor in CD11b⁺Gr1⁺ cells: Key role of Stat3 signaling. *J. Biol. Chem.* 287, 19574-19584, 2012.
190. Chung, AS, Kowanetz, M, Wu, X, Zhuang, G, Ngu, H, Finkle, D, Komuves, L, Peale FV, Ferrara, N. Differential drug-class specific metastatic effects following treatment with a panel of angiogenesis inhibitors *J. Pathol.* 227, 404-416, 2012.
191. Singh, M, Couto, SS, Forrest, WF, Lima, A, Cheng, JH, Molina, R, Long, JE, Hamilton, P, McNutt, A, Kasman, I, Nannini, MA, Reslan, HB, Cao, TC, Ho, CC, Barck, KH, Carano, RA, Foreman, O, Eastham-Anderson, J, Jubb, AM, Ferrara, N, Johnson, L. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumor models. *J. Pathol.* 227, 417-430, 2012.
192. Argaw, TA, Asp, L, Zhang, J, Navrazhina, K, Pham, T, Mariani, JN, Mahase, S, Dutta, DJ, Kramer, EG, Ferrara, N, Sovroniev, MV, John, GR. Astrocyte-derived VEGF drives blood-brain barrier disruption and neuropathology in inflammatory and demyelinating CNS disease. *J. Clin. Invest.* 122, 2454-2468, 2012.
193. Willenborg, S, Lucas, T, van Loo, G, Knipper, JA, Krieg, TM, Haase, I, Brachvogel, B, Hammerschmidt, M, Nagy, A, Ferrara, N, Pasparakis, M, Eming, SA. CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. *Blood.* 120, 613-625, 2012.
194. Zhuang, G, Wu, X, Jiang, Z, Kasman, I, Yao, J, Guo, Y, Oeh, J, Modrusan, Z, Bais, C, Sampath, D, Ferrara, N. Tumor secreted miR-9 promote endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. *EMBO J.* 31, 3513-3523, 2012.
195. Liu, Y, Berendsen, AD, Jia, S, Lotinun, S, Baron, R, Ferrara, N, Olsen, BR. Intracellular VEGF regulates the balance between osteoclast and adipocyte differentiation. *J. Clin. Invest.* 122, 3101-3113, 2012.
196. Ben Shoam, A, Malkinson, G, Krief, S, Schwartz, Y, Ely, Y, Ferrara, N, Yaniv, K, Zelzer, E. S1P1 inhibits sprouting angiogenesis during vascular development. *Development.* 139, 3859-3869, 2012.
197. Jin, J, Sison, K, Li, C, Tian, R, Wnuk, M, Sung, HK, Jeannson, M, Zhang, C, Tucholska, M, Jones, N, Kerjacki, D, Shibuya, M, Fantus, G, Gerber, HP, Ferrara, N, Pawson, T, Quaggin, SE. Soluble Flt-1 regulates glomerular barrier function. *Cell.* 151, 384-399, 2012.
198. Snuderl, M, Batista, A, Kirkpatrick, ND, Ruiz de Almodovar, C, Riedemann, L, Walsh, EC, Anolik, R, Huang, Y, Martin, JD, Kamoun, W, Knevels, E, Schmidt, T, Farrar, CT, Vakoc, BJ, Mohan, N, Chung, E, Roberge, S, Peterson, T, Bais, C, Zhelyazkova, BH, Yip, S, Hasselblatt, M, Rossig, C, Niemeyer, E, Ferrara, N, Klagsbrun, M, Duda, D, Fukumura, D, Xu, L, Carmeliet, P, Jain, RK. Targeting placenta growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. *Cell.* 152, 1065-1067, 2013.
199. Stefater, JA, Rao, S, Bezold, K, Aplin, AC, Nicosia, RF, Pollard, J, Ferrara, N, Lang, R. Macrophage Wnt-Calcineurin-Flt1 signaling regulates wound angiogenesis and repair. *Blood.* 121, 2574-2578, 2013.

200. Rao, S, Chun, C, Fan, J, Kpfron, JM, Hegde, RS, Ferrara, N, Copenhagen, Lang, RA. A melanopsin-dependent fetal light response regulates mouse eye development. *Nature*. 494, 243-246, 2013.
201. Phan, V, Wu, X, Cheng, J, Sheng, R, Chung, A, Zhuang, G, Tran, C, Song, Q, Kowanetz, M, Sambrone, A, Tan, M, Meng, YG, Jackson, EL, Peale, F, Junttila, M, Ferrara, N. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. *Proc. Natl. Acad. Sci. USA*. 110, 6079-6084, 2013.
202. Zhuang, G, Yu, K, Jiang, Z, Chung, A, Yao, J, Soriano, R, Haley, B, Blackwood, E, Sampath, D, Bais, C, Lill, J, Ferrara, N. VEGF-regulated phospho-proteome implicates the mTORC2-FoxO1 axis in VEGF signaling and RTK reprogramming of human endothelial cells. *Science Signal*. 6, ra25, 2013.
203. Luo, L, Uehara, H, Zhang, X, Das, SK, Olsen, T, Holt, D, Simonis, JM, Jackman, K, Singh, N, Miya, TR, Huang, W, Ahmed, F, Bastos-Carvalho, A, Le, YZ, Mamalis, C, Chiodo, VA, Hauswirth, WW, Baffi, J, Lacal, PM, Orecchia, A, Ferrara, N, Gao, G, Young-hee, K, Fu, Y, Owen, L, Albuquerque, R, Baehr, W, Thomas, K, Li, DY, Chalam, KV, Shibuya, M, Grisanti, S, Wilson, DJ, Ambati, J, Ambati. Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. *eLife* 2, e00324, 2013.
204. Brauer, MJ, Zhuang, G, Schmidt, M, Yao, J, Wu, X, Kaminker, J, Jurinka, S, Kolumam, G, Chung, AS, Jubb, A, Modrusan, Z, Phillips, H, James, D, Haley, B, Clermont, A, Cheng, JH, Yang, SX, Swain, S, Scherer, S, Koeppen, H, Yeh, R-F, Choi, YJ, Yue, P, Stephan, J-P, Hegde, P, Ferrara, N, Singh, M, Bais, C. Anti-VEGF treatment targets a discrete and molecularly distinguishable compartment within tumor vasculature in mice and humans. *Clin. Cancer Res*. 19, 3681-3692, 2013.
205. Sampath, D, Oeh, J, Wayatt, SK, Cao, T, Koeppen, H, Robilard, L, Oo, CCK, Ross, J, Zhang, G, Bou-Reslan, H, Vitorino, P, Barck, KH, Van Bruggen, N, Vijapurkar, U, Ferrara, N, Friedman, LS, Carano, RAD. Multi-modal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an anti-vascular response in vivo. *Neoplasia*. 15, 694-671, 2013.
206. Zhong, C, Wang, J, Li, B, Xiang, H, Ultsch, M, Coons, M, Wong, T, Chiang, NY, Clark, S, Clark, R, Gribbling, P, Suto, E, Barck, K, Corpuz, R, Takkar, R, Lee, WP, Yao, J, Adams, C, Kelley, R, Wang, W, Ferrara, N. Development and preclinical characterization of a humanized antibody targeting CXCL12. *Clin. Cancer Res*. 19, 4433-4445, 2013.
207. Chung, AS, Wu, X, Zhuang, G, Ngu, H, Zhang, N, Kasman, I, Jiang, Z, Meng, G, Peale, F, Ouyang, W, Ferrara, N. IL-17 mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. *Nature Med*. 19, 1114-1123, 2013.
208. Kim, M, Park, HJ, Seol, JW, Jang, JY, Cho, Y-S, Kim, KR, Choi, Y, Lydon, JP, DeMayo, FJ, Shibuya, M, Ferrara, N, Sung, H-K, Nagy, Alitalo, K, Koh, GY. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodeling during pregnancy. *EMBO Mol. Med*. 5, 1415-1430, 2013.
209. Lu, N, Sargent, KM, Clopton, DT, Pohlmeier, WE, Brauer, VM, McFee, RM, Weber, SJ, Ferrara, N, Silversides, DW, Cupp, AS. Loss of vascular endothelial growth factor A (VEGFA) isoforms in the testes of male mice causes subfertility, reduces sperm numbers

- and alters expression of genes that regulate undifferentiated spermatogonia. *Endocrinology*. 154, 4790-4802, 2013.
210. Fan, J, Ponferrada, VG, Sato, T, Vemaraju, S, Fruttiger, M, Gerhardt, H, Ferrara, N, Lang RA. Crim1 maintains retinal vascular stability during development by regulating endothelial cell vegfa autocrine signaling. *Development*. 141, 448-459, 2014.
 211. Moriya, J, Wu, X, Zavala-Solorio, J, Ross, J, Liang, X-H, Ferrara, N. PDGF-C promotes revascularization in ischemic limbs of diabetic mice. *J. Vasc. Surg.* 59, 1402-1409, 2014.
 212. Yang, J, Wang, X, Fuh, G, Yu, L, Wakshull, E, Kosraviani, M, Demeule, B, Lium J, Shire, SJ, Ferrara, N, Yadav, S. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. *Mol. Pharmaceutics*. 11, 3421-3430, 2014.
 213. Milgrom-Hoffman, M, Michailovici, I, Ferrara, N, Zelzer, E, Tzahor, E. Endothelial cells regulate neural crest and second heart field morphogenesis. *Biol. Open* 3, 679-688, 2014.
 214. Guerit, S, Allain, AE, Leon, C, Cazenave, W, Ferrara, N, Branchereau, P, Bikfalvi, A. VEGF modulates synaptic activity in the developing spinal cord. *Dev. Neurobiol.* 74, 1110-1122, 2014.
 215. Eshkar-Oren, I, Krief, S, Ferrara, N, Elliott, AM, Zelzer, E. Vascular patterning regulated interdigital cell death by a ROS-mediated mechanism. *Development*. 142, 672-680, 2015.
 216. Moriya, J, Ferrara, N. Protein Kinase C- α inhibits angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells. *Cardiovasc. Diabetol.* 14 (1) 19, 2015.
 217. Sargent, KM, Lu, N, Clopton, DT, Pohlmeier, WE M Brauer, VM, Ferrara, N, Silversides, DW, Cupp, AS. Loss of Vascular Endothelial Growth Factor A (VEGFA) Isoforms in Granulosa Cells Using *pDmrt-1-Cre* or *Amhr2-Cre* Reduces Fertility by Arresting Follicular Development and by Reducing Litter Size in Female Mice. *Plos One* 10 (2), Feb. 6, 2015.
 218. Selvaraj, D, Gangadharan, V, Michalski, CW, a Kurejova, M, Stösser, S Srivastava, K, Schweizerhof, M, Waltenberger, J, Ferrara, N, Heppenstall, P, Shibuya, M, Augustin, HG, Kuner, R. A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain. *Cancer Cell*, 27, 780-796, 2015.
 219. Espina, M, Arcinue, CA, Ma, F, Camacho, N, Barteselli, G, Mendoza, N, Ferrara, N, Freeman W. Outer retinal tubulations response to anti-VEGF treatment. *Brit. J. Ophthalmol.* 100, 819-823, 2016.
 220. Osterberg, N Ferrara, N, Vacher, J S Gaedicke, G Niedermann, Weyerbrock, A, Doostkam, S, Schaefer, HE, Plate, KH, Machein, MR. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. *Neuro Oncol.* 18, 939-949, 2016.
 221. Jais, A, Solas, M, Backes, H, Chaurasia, B, Kleinridders, A, Theurich, S, Mauer, J, Steculorum, SM, Happel, B, Goldau, J, Alber, J, Forstafer, CY, Eming, SA, Schwaniger,

- M, Ferrara, N, Karsenty, G, Bruning, JE. Myeloid-cell derived VEGF maintains brain glucose uptake and limits cognitive impairment in obesity. *Cell*. 165, 882-895, 2016.
222. Xin, H, Zhong, C, Nudleman, E, Ferrara, N. Evidence for pro-angiogenic functions of VEGF-Ax. *Cell*. 167, 275-284, 2016.
 223. Pitulescu, ME, Schmidt, I, Antoine, T, Berkenfeld, F, Ehling, M, Biljes, D, Rocha, SF, Stehling, M, Langen, UH, Nagasawa, T, Ferrara, N, Borggrefe, T, Adams, RH. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. *Nat. Cell Biol.* 19, 915-927, 2017.
 224. Heiken, H, Dieguez-Hurdado, R, Schmidt, I, Nakayama, M, Jeong, H-W, Arf, H, Adams, S, Ferrara, N, Adams, RH. Pericytes restrict VEGF-induced endothelial sprouting through VEGFR-1. *Nature Commun.* 8, 1574. 2017.
 225. Liang, W, Li, Q, Ferrara, N. Metastatic growth instructed by neutrophil-derived transferrin. *Proc. Natl. Acad. Sci. USA*. 115, 11060-11065, 2018.
 226. Protopsaltis, N, Liang, W, Nudleman, E, Ferrara, N. Interleukin-22 promotes tumor angiogenesis. *Angiogenesis*. 22, 311-323, 2019.
 227. Gilardi, M, Wang, Z, Proietto, M, Chilla', A, Calleja-Valera, J, Goto, Y, Vanoni, M, Janes, MR, Mikulski, Z, Gualberto, A, Molinolo, AA, Ferrara, N, Gutking, JS, Burrows, F. Tipifarnib, as a precision therapy for HRAS-mutant head and Neck squamous cell carcinomas. *Mol. Cancer Ther.* 19, 1784-1796, 2020.
 228. Itatani, Y, Zhong, C, Yamamoto, M, Molinolo AA, Ruppel, J, Hegde, P, Taketo, MM, Ferrara, N. Suppressing neutrophil-dependent angiogenesis, abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. *Proc. Natl. Acad. Sci. USA*. 117, 21598-21608, 2020.
 229. Zhong, C, Li, P, Argade, S, Liu, L, Chilla', A, Liang, W, Xin, H, Eliceiri, B, Choudhury, B, Ferrara, N. Inhibition of protein glycosylation, is a novel pro-angiogenic strategy that acts through activation of stress pathways. *Nature Commun.* 11, 6330, 2020.
 230. Xin, H, Biswas, N, Li, P, Zhong, C, Nudleman, E, Ferrara, N. Long-Acting VEGF Inhibitors for Treatment of Intraocular Neovascular Disorders. *Proc. Natl. Acad. Sci. USA*. 118, e192125118, 2021.
 231. Li, P, Li, Q, Biswas, N, Xin, H, Diemer, T, Liu, L, Perez Gutierrez, L, Paternostro, G, Piermarocchi, C, Domanskyi, S, Wang, RK, Ferrara, N. LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: Implications for prevention of geographic atrophy. *EMBO Mol. Med.* e14511, 2022.
 232. Domanskyi, S, Hakansson, A, Meng, M, Pham, BK, Graff Zivin, J.S., Piermarocchi, C, Paternostro, G, Ferrara, N. Naturally occurring combinations of receptors from single cell transcriptomics in endothelial cells. *Sci. Reports*, 12, 5807, 2022.
 233. Deichaite, I, Sears, TJ, Sutton, L, Rebibo, D, Morgan, K, Nelson, T, Rose, B, Tamayo, P, Ferrara, N, Asimakopoulos, F, Carter, H. Differential regulation of TNFa and IL-6

- expression contributes to immune evasion in prostate cancer. *J. Transl. Med.* 20:527, 2022.
234. Marra, K, Chen, JS, Robles-Holmes, HK, Miller, J, Wei, G, Aguilar, E, Ideguchi, Y, Ly, KB, Prenner, S, Erdogmus, D, Ferrara, N, Campbell, JP, Friedlander, M, Nudleman, E. Development of a semi-automated computer-based tool for the quantification of vascular tortuosity in the murine retina. *Opthalmol Sci.* 2023, Dec. 6;4(3):100439235.
 235. Chen, JS, Marra, K, Robles-Holmes, HK, Miller, J, Wei, G, Aguilar, E, Ideguchi, Y, Ly, KB, Prenner, S, Erdogmus, D, Ferrara, N, Campbell, JP, Friedlander, M, Nudleman, E. Applications of Deep Learning: Automated Assessment of Vascular Tortuosity in Mouse Models of Oxygen-Induced Retinopathy. *Opthalmol Sci.* 2023 May 25;4(1):100338. eCollection 2024 Jan-Feb.
 236. Marra, K, Chen, JS, Robles-Holmes, HK, Ly, KB, Miller, J, Wei, G, Aguilar, E, Bucher, F, Ideguchi, Y, KalaW, FGP, Lin, AC, Ferrara, N, Campbell, JP, Friedlander, M, Nudleman, E. Development of an Open-Source Dataset of Flat-Mounted Images for the Murine Oxygen-induced Retinopathy Model of Ischemic Retinopathy. *Trans Vis. Sci Technol*, 2024 Dec. 2 13(12) 4.
 237. Biswas, N, Mori, T, Kumar Chetty Nagaraj, K, Xin, H, Diemer, T, Li, P, Su, Y, Piermarocchi, C, Ferrara, N. Adenosine diphosphate stimulates VEGF-independent choroidal endothelial cell proliferation: A potential escape from anti-VEGF therapy. *Proc. Natl. Acad. Sci. USA.* Jan. 2025. 122 (4) e2418752122.

Reviews and editorials

1. Ferrara, N, Goldsmith, PG, Fujii, DK, Weiner, R. Culture and characterization of follicular cells from bovine anterior pituitary and pars tuberalis. *Methods Enzymol.* 124, 245-253, 1986.
2. Gospodarowicz, D, Ferrara, N, Schweigerer, L, Neufeld, G. Structural characterization and biological functions of fibroblast growth factor. *Endocr. Rev.* 8, 95-114, 1987.
3. Gospodarowicz, D, Ferrara, N. Fibroblast growth factor and the control of pituitary and gonad development and function. *J. Ster. Biochem.* 32, 183-191, 1989.
4. Ferrara, N, Leung DW, Cachianes, G, Winer J, Henzel, WJ. Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculo-stellate cells. *Methods Enzymol.* 198, 391-404, 1991.
5. Ferrara, N, Houck KA, Jakeman LB, Winer, J, Leung DW. The vascular endothelial growth factor family of polypeptides. *J. Cell. Biochem.* 47, 211-218, 1991.
6. Ferrara, N, Houck, K, Jakeman, L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. *Endocr. Rev.* 13, 18-32, 1992.
7. Ferrara, N. Vascular endothelial growth factor. *Trends Cardiovasc. Med.* 3, 244-250, 1993.
8. Ferrara, N. The role of VEGF in pathological angiogenesis. *Breast Cancer Res. Treat.* 36, 127-137, 1995.

9. Ferrara, N. Leukocyte adhesion - Missing link in angiogenesis. *Nature*. 376, 467, 1995.
10. Ferrara, N, Heinshon, H, Walder, C, Bunting, S, Thomas, GR. The regulation o blood vessel growth by vascular endothelial growth factor. *Ann. N.Y. Acad. Sci.* 752, 246-256, 1995.
11. Ferrara, N. Vascular endothelial growth factor -The trigger for neovascularization in the eye. *Lab. Invest.* 72, 615-618, 1995.
12. Ferrara, N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. *Curr. Opin. Nephrol. Hypertens.* 5, 35-44, 1996.
13. Ferrara, N. Natural killer cells, adhesion and tumor angiogenesis. *Nature Med.* 2, 971-972, 1996.
14. Ferrara, N. The regulation of angiogenesis by vascular endothelial growth factor. *Trends Exp. Clin Med.* 6, 393-404, 1996.
15. Ferrara, N. Vascular endothelial growth factor. *Eur. J. Cancer.* 32A, 2413-2422, 1996.
16. Ferrara, N, Davis-Smyth, T. The biology of vascular endothelial growth factor. *Endocr. Rev.* 18, 4-25, 1997.
17. Ferrara, N. VEGF: Molecular and biological aspects. *Curr. Top. Microbiol. Immunol.* 237, 1-30, 1999.
18. Ferrara, N. The role of VEGF in the regulation of angiogenesis. *Kidney Int.* 56, 794-814, 1999.
19. Ferrara, N. Molecular and biological properties of VEGF. *J. Mol. Med.* 77, 527-543, 1999.
20. Ferrara, N, Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. *Nature Med.* 5, 1359-1364, 1999.
21. Ferrara, N. VEGF and the regulation of angiogenesis. *Rec. Prog. Horm. Res* 55, 15-36, 2000.
22. Ferrara, N. VEGF: An update on biological and therapeutic aspects. *Curr. Opin. Biotech.* 11, 617-624, 2000.
23. Gerber, HP, Ferrara, N. Angiogenesis and bone growth. *Trends Cardiovasc. Med.* 10, 223-228, 2000.
24. Ferrara, N. The role of VEGF in the regulation of physiological angiogenesis. *Am. J. Physiol.* 280, C1358-1366, 2001.
25. Ferrara, N, Gerber HP. The role of VEGF in angiogenesis. *Acta Haematol.* 106, 148-156, 2001.

26. LeCouter, J, Ferrara, N. EG-VEGF and the concept of tissue-specific angiogenic growth factors. *Semin. Cell Dev. Biol.* 13, 3-8, 2002.
27. LeCouter, J, Lin, R, Ferrara, N. EG-VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis *Nature Med.* 8, 913-917, 2002.
28. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. *Nature Rev. Cancer.* 2, 795-803, 2002.
29. Ferrara, N. Role of VEGF in physiological and pathological angiogenesis: therapeutic implications. *Sem. Oncol.* 29, 10-14, 2002.
30. LeCouter, J, Lin, R, Ferrara, N. The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. *Cold Spring Harbor Symp. Quant. Biol.* 67, 217-221, 2002.
31. Gerber, HP, Ferrara, N. Role of VEGF in normal and neoplastic hematopoiesis. *J. Mol. Med.* 81, 20-31, 2003.
32. LeCouter, J, Ferrara, N. EG-VEGF and Bv8: A novel family of tissue-selective mediators of angiogenesis, endothelial phenotype and function. *Trends Cardiovasc. Med.* 13, 276-282, 2003.
33. Ferrara, N, Gerber, HP, LeCouter, J. The biology of VEGF and its receptors. *Nature Med.* 9, 669-676, 2003.
34. Ferrara, N. LeCouter, J, Lin, R, Peale, F. EG-VEGF and Bv8: A novel family of tissue-restricted angiogenic factors. *Biochim. Biophys. Acta.* 1654, 69-78, 2004.
35. Ferrara, N, Hillan, K, Gerber, HP, Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nature Rev. Drug Discov.* 3, 391-400, 2004.
36. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr. Rev.* 25, 581-611, 2004.
37. Ferrara, N. LeCouter, J. EG-VEGF and Bv8. *Ann. N.Y. Acad. Sci.* 1014, 50-57, 2004.
38. Ferrara, N. VEGF as a target for anticancer therapy. *The Oncologist.* 9 Suppl 1, 2-10, 2004.
39. Ferrara, N. VEGF isoforms implicated in choroidal neovascularization. *Ophthalmol. Times.* Suppl. 5, 29, 7-9, 2004.
40. Gerber, HP, Ferrara, N. The pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. *Cancer Res.* 65, 671-680, 2005.
41. Ferrara, N, Hillan, K, Novotny, W. Bevacizumab (AvastinTM), a humanized anti-VEGF antibody for cancer therapy. *Biochem. Biophys. Res. Commun.* 333, 328-335, 2005.

42. Gasparini, G, Longo, R, Toi, M, Ferrara, N. Antiangiogenic inhibitors: a new therapeutic strategy in oncology. *Nature Clin. Pract. Oncol.* 2, 562-577, 2005.
43. Ferrara, N. Kerbel, RS. Angiogenesis as a therapeutic target. *Nature.* 438, 967-974, 2005.
44. Kowanetz, M, Ferrara, N. VEGF signaling pathways: therapeutic perspectives. *Clin. Cancer Res.* 12, 5018-5022, 2006.
45. Red-Horse, K, Ferrara, N. Imaging tumor angiogenesis. *J. Clin. Invest.* 116, 2585-2587, 2006.
46. Ferrara, N, Damico, L, Shams, N, Lowman, H, Kim, R. Development of ranibizumab, an anti-VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration. *Retina.* 26, 859-870, 2006.
47. Ferrara, N. Mass, RD, Campa, C, Kim, R. Targeting VEGF-A to treat cancer and age-related macular degeneration. *Annu. Rev. Med.* 58, 491-504, 2007.
48. Shojaei, F, Ferrara, N. Antiangiogenesis to treat cancer and age-related macular degeneration. *Lab. Invest.* 87, 227-230, 2007.
49. Red-Horse, K, Crawford, Y, Shojaei, F, Ferrara, N. Endothelium-microenvironment interactions in the developing embryo and in the adult. *Dev. Cell.* 12, 181-194, 2007.
50. Red-Horse, K, Ferrara N. Vascular targeting via caveolae. *Nature Biotechnol.* 25, 5-7, 2007.
51. Shojaei, F, Ferrara, N. Antiangiogenic therapy for cancer: an update. *Cancer J.* 13, 345-348, 2007.
52. Ferrara, N, Damico, L, Shams, N, Lowman, H, Kim, R. Reply- Letter to the Editor *Retina.* 27, 1156-1158, 2007.
53. Shojaei, F, Ferrara, N. Refractoriness to anti-VEGF treatment: Role of myeloid cells. *Cancer Res.* 68, 5501-5504, 2008.
54. Shojaei, F, Zhong, C, Wu, X, Yu, L, Ferrara, N. Role of myeloid cells in tumor angiogenesis and growth. *Trends Cell Biol.* 18, 372-378, 2008.
55. Shojaei, F, Ferrara, N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. *Drug Resist. Updat.* 11, 219-230, 2008.
56. Crawford, Y, Ferrara, N. Mouse models to investigate anti-cancer effects of VEGF inhibitors. *Methods Enzymol.* 445C, 125-139, 2008.
57. Bikfalvi, A, Ferrara, N. Remembering Jean Plouet, pioneer of angiogenesis research in France and co-discoverer of vascular endothelial growth factor. *Cancer Res.* 68, 10004, 2008.

58. Crawford, Y, Ferrara, N. VEGF inhibition: insights from preclinical and clinical studies. *Cell Tissue Res.* 335, 261-269, 2009.
59. Ferrara, N. History of discovery- Vascular endothelial growth factor. *Arteriosc. Thromb. Vasc. Biol.* 29, 789-791, 2009.
60. Crawford, Y, Ferrara, N. Tumor- and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. *Trends Pharmacol. Sci.* 30, 624-630, 2009.
61. Ferrara, N. VEGF-A, a critical regulator of blood vessel growth. *Eur. Cytok. Netwk.* 20, 158-163, 2009.
62. Ferrara, N. Pathways mediating VEGF-independent angiogenesis. *Cytok. Growth Factor Rev.* 21, 21-26, 2010.
63. Chung, AS, Ferrara, N. Targeting the tumor microenvironment with Src kinase inhibition. *Clin. Cancer Res.* 16, 775-777, 2010.
64. Ferrara, N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating VEGF action. *Mol. Biol. Cell.* 21, 687-689, 2010.
65. Coffelt, SB, De Palma, M, Naldini, L, Coussens, LM, Ferrara, N, Brown, JM, Lewis, CE. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. *Am. J. Pathol.* 176, 1564-1576, 2010.
66. Ferrara, N. Role of myeloid cells in VEGF-independent angiogenesis. *Curr. Opin. Hematol.* 17, 219-224, 2010.
67. Chung, AS, Lee, J, Ferrara, N. Targeting the tumor vasculature: insights from physiological angiogenesis. *Nat. Rev. Cancer.* 10, 505-514, 2010.
68. Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. *Nature Med.* 16, 1107-1111, 2010.
69. Lewis, CE, Ferrara, N. Multiple effects of angiopoietin 2 blockade in tumors. *Cancer Cell.* 19, 431-433, 2011.
70. Chung, AS, Ferrara, N. Developmental and pathological angiogenesis. *Annu. Rev. Cell Develop. Biol.* 27, 563-584, 2011.
71. Singh, M, Ferrara, N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. *Nature Biotechnol.* 30, 648-657, 2012.
72. Miller, JD, Le Couter, J, Strauss, E, Ferrara, N. Vascular endothelial growth factor in intraocular vascular disease. *Ophthalmology.* 120, 106-114, 2013.
73. Ferrara, N. Discovery of VEGF, a key regulator of angiogenesis. *Eur. J. Neurodegen. Dis.* 2, 81-87, 2013.
74. Moriya, J, Ferrara, N. Inhibiting the response to VEGF in diabetes. *Sci. Signal.* 7, pe1, 2014.

75. Ferrara, N, Adamis, AP. Ten years of anti-vascular endothelial growth factor therapy. *Nat. Rev. Drug Discov.* 15, 385-403, 2016.
76. Liang, W and Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. *Cancer Immunol. Res.* 4, 83-91, 2016.
77. Ferrara, N. VEGF and Intraocular Neovascularization: From Discovery to Therapy *Transl. Vis. Sci. Technol.* 5 (2), 10, 2016.
78. Ferrara, N. Commentary on “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders”. *Cancer Res.* 76, 4913-4915, 2016.
79. Ferrara, N. Microvascular density as a predictive biomarker for bevacizumab survival benefit in ovarian cancer: Back to first principles? *J. Natl. Cancer Inst.* Vol 109, 10.1093/jnci/djx067, 2017.
80. Negri, L, Ferrara, N. The Prokineticins: Neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. *Physiol. Rev.* 98, 1055-1082, 2018.
81. Nowak-Slowinska, P, Alitalo, K, Allen, E, Anisimov, A, Aplin, AC, Auerbach, R, Augustin, HG, Bates, DO, *et al.* Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis.* 21, 425-532, 2018.
82. Apte, R, Chen, DS, Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. *Cell.* 176, 1248-1264, 2019.
83. Liang, W, Ferrara, N. Iron metabolism in the tumor microenvironment: contributions of innate immune cells. *Frontiers Immunol.* 11,626812, 2021.
84. Li, P, Ferrara, N. Vascular heterogeneity: VEGF receptors make blood vessels special. *J. Exp. Med.* 219: e20212539, 2022.
85. Cao, Y, Langer, R, Ferrara, N. Targeting Angiogenesis in Oncology, Ophthalmology and Beyond. *Nat. Rev. Drug Discov.* 22, 476-495, 2023.
86. Perez-Gutierrez, L, Ferrara, N. Biology and therapeutic targeting of VEGF-A. *Nat. Rev. Mol. Cell Biol.* 24, 816-834, 2023.
87. Nebigil, C, Vincenzi, M, Jouve, A, Lattanzi, R, Miele, R, Benharouga, M, Alfaidi-Benharougam, N, Migrenne-Li, S, Kanthasami, A, Porcionatto, M, Ferrara, N, Tetko, I, Desaubry, L. Therapeutic potential of targeting prokineticin receptors in disease. *Pharmacol. Rev.* 75,1167-1199, 2023.
88. Vestweber, d, Claesson-Welsh, L, McDonald, DM, Williams, T, Schwartz, MA, Gavins, FNE, van Buul, J, Gamble, J, Vadas, M, Annex, BH, Messe, SR, Perretti, M, Andre, H, Ferrara, N, Hla, T, Noursharg, S, Simons, M. Report from the 2023cworkshop on endothelial permeability, edema and inflammation. *Nat. Cardiovasc. Res.* 2, 1120-1124, 2023.

89. Perez-Gutierrez, L, Li, P, Ferrara N. Endothelial heterogeneity: the multiple facets of the prism. *FEBS J.* 291, 3287-3292, 2024.
90. Mori, T, Kumar, RNN, Ferrara, N. Elucidating VEGF biology: A journey of discovery and Clinical Translation. Centennial Collection *Arteriosc. Thromb. Vasc. Biol.* 44, 2361-2365, 2024.

Book chapters

1. Iasonni, VM, Bulletti, C, Fuschini, Ferrara, N, Induzione dell'ovulazione nella sterilita' da iperprolattinemia. Boll. Soc. Med. Chir. Modena, 80(2), 35-42, 1980.
2. Scapagnini, U, Canonico, PL, Ferrara, N. Psiconeuroendocrinologia. Liviana Press, Padua, 1982.
3. Nicoletti, F, Ferrara, N, Patti, Condorelli, DF, DeSimone, D, Scarzella, Tigano, G. Neuromodulatori steroidei e sistema extrapiramidale: effetto del medrogestone. In: Proceedings Italian Parkinson's Disease Study Group. 1982.
4. Scapagnini, U, Clementi, G, Prato, A, Ferrara, N, Nicoletti, F, Patacchioli, F, Angelucci, A. Behavioral and neuroendocrine actions of calcitonin. In: Neuropeptides, neurotransmitters and the regulation of endocrine processes. Endröczy, E, Ed. Elsevier/North Holland, pp 231-240, 1983.
5. Nicoletti, F, Ferrara, N, Bernardini, R, Clementi, G, Patti, F, Di Giorgio, RM. Changes in medial basal hypothalamus gabaergic activity in conditions of hyperprolactinemia. In: Neuropeptides, neurotransmitters and the regulation of endocrine processes. Endröczy E, Ed. Elsevier/North Holland, pp 345-353, 1983.
6. Gospodarowicz, D, Ferrara, N. The control of cell proliferation and differentiation by fibroblast growth factor. In: Neuronal plasticity and trophic factors. Biggio, G, Spano, P, Toffano, G, Gessa, GL, Eds. Liviana Press/Springer Verlag, pp 53-75, 1988.
7. Weiner, RI, Findell, P, Ferrara, N, Clapp, C, Schechter J. Arteriogenesis and the etiology of prolactinomas. In: Progress in Endocrinology 1988. Imura, I, Ed. Elsevier, Amsterdam, pp 559-566, 1988.
8. Ferrara, N. Fattori di crescita. In: Psiconeuroendocrinoimmunologia. Scapagnini, U, Ed. Liviana Press, Padua. pp 111-155, 1989.
9. Ferrara, N, Henzel, WJ, Louie, A. Identification and purification of a novel angiogenic factor secreted by pituitary folliculo-stellate cells. In: Molecular and clinical advances in pituitary disorders. Melmed, S, Robbins, RJ, Eds. Blackwell Sci. Publ., Boston, pp 105-118, 1991.

10. Ferrara, N, Leung, DW, Phillips, HS. Molecular characterization and distribution of vascular endothelial growth factor. In: Neuroendocrine Perspectives. MacLeod, RB, Müller, EE, Eds. Springer Verlag, Vol. 9 pp 127-150, 1991.
11. Ferrara, N, Park, JE. Folliculostellate cells as a source of endothelial cell growth factors. In: Molecular and Clinical Advances in Pituitary Disorders - 1993. Melmed, S. Ed. Endocrine Res. and Educ. Inc. Los Angeles, CA, pp 121-126, 1993.
12. Ferrara, N, Park, JE. Vascular endothelial growth factor (VEGF). In: Guidebook to Cytokines and their Receptors. Nicola, N, Ed. Oxford Univ. Press. pp. 232-234, 1995.
13. Park, JE, Ferrara, N. Vascular endothelial growth factor (VEGF) receptors. In: Guidebook to Cytokines and their Receptors. Nicola, N, Ed. Oxford Univ. Press. pp. 235-237, 1995.
14. Ferrara, N, Park, JE, Walder, C, Bunting, S, Thomas GR. The regulation of normal and pathological angiogenesis by vascular endothelial growth factor. In: Cardiovascular Diseases 2. Gallo, L, Ed. Plenum Press. pp. 133-144, 1995.
15. Ferrara, N. The biology of VEGF. In: Angiogenesis. Molecular, cellular and clinical aspects. Maragoudakis, M, Lelkes, P, Eds. Plenum Press. pp 73-83, 1996.
16. Ferrara, N, Keyt, B. Vascular endothelial growth factor. Basic biology and clinical implications. In: Regulation of angiogenesis. Rosen, E, Goldberg, ID, Eds. Springer Verlag. pp 209-232, 1997.
17. Ferrara, N. The role of vascular endothelial growth factor in the regulation of blood vessel growth. In: Tumour angiogenesis. Bicknell, R, Lewis, CE, Ferrara, N, Eds. Oxford Univ Press. pp 185-199, 1997.
18. Ferrara, N. The biology of VEGF, a specific regulator of angiogenesis. In: Growth factors and wound healing: basic science and potential clinical applications. Ziegler, T, Pierce, G, Herndon, D, Eds. Springer Verlag. pp 317-342, 1997.
19. Ferrara, N. Role of VEGF in the regulation of angiogenesis. In: Antiangiogenic agents in cancer therapy. Teicher, BA, Ed. Humana Press. pp 119-141, 1999.
20. Ferrara, N, Gerber, HP. VEGF. In: Angiogenesis in cardiovascular disease. Ware, JA, Simons, M, Eds. Oxford Univ. Press. pp 101-127, 1999.
21. Ferrara, N, Gerber, HP. VEGF. Molecular and biological aspects. In: Advances in Organ Biology vol 7 - Coronary angiogenesis. Rakusan, K, Ed. JAI Press. pp 25-57, 1999.
22. Ferrara, N. The role of VEGF in the regulation of angiogenesis. In: Angiogenesis in Health and Disease. Rubanyi, GM, Ed. Marcel Dekker, pp 47-63, 1999.
23. Ferrara, N. The role of VEGF in angiogenesis. In: Angiogenesis inhibitors and stimulators: potential therapeutic implications. Mousa, S, and D'Amato, R, Eds. Landes Biosci, pp 61-83, 2000.

24. Ferrara, N. Angiogenesis inhibitors. In: Tumor angiogenesis and microcirculation. D'Amore PA, and Voest E. Eds. Marcel Dekker, pp 399-430, 2001.
25. Ferrara, N. VEGF, a key regulator of physiological angiogenesis. In: Vascular morphogenesis in the Female Reproductive Tract. Augustin, H, Iruela-Arispe, L, Rogers, PAW, Smith, SK, Eds. Birkhauser, pp 149-165, 2001.
26. Ferrara, N. VEGF and its receptors. In: VEGF and Cancer. Harmey, JH, Ed. Kluwer, pp 1-25, 2004.
27. Ferrara, N. VEGF and its receptors. In: Atherosclerosis XIII. Proc. 13th Intl. Atherosclerosis Conf., Kyoto, Japan. Matsuzawa, Y, Kita, T, Nagai, R, Teramoto, T, Eds. Elsevier. pp 283-286, 2004.
28. Ferrara, N. The role of VEGF in physiological and pathological angiogenesis. In: Mechanisms of Angiogenesis. Clauss, M, Breir, G, Eds. Birkhauser, pp. 209-231, 2005.
29. Ferrara, Lin, R, LeCouter, J. Vascular bed specific signaling and tumor angiogenesis. In: Endothelial cells in health and disease. Aird, W, Ed. Taylor & Francis, pp 203-216, 2005.
30. Ferrara, N. VEGF: Pathophysiology and Clinical implications. In: Angiogenesis: from basic science to clinical applications. Ferrara, N, Ed. Taylor & Francis, pp 1-36, 2006.
31. Ferrara N. Targeting VEGF. In: Antiangiogenic Cancer Therapy. Davis, DW, Herbst, RS, Abruzzese, JA, Eds. CRC Press, pp 23-41, 2008.
32. Ferrara, N. The pathophysiology and clinical applications of VEGF. In: Tumor angiogenesis. Marme', D, Fusenig, N. Eds. Springer-Verlag. pp 89-108, 2008.
33. Ferrara, N. VEGF: Basic biology and clinical applications. In: Angiogenesis: An integrative approach from science to medicine. Figg, W, Folkman J, Eds. Springer, pp 345-352, 2008.
34. Ferrara, N. Targeting VEGF to treat cancer and other disorders. In: Proc. 38th Intl. Symposium Princess Takamatsu Cancer Res. Fund. Nakagama, H, Dove WD, Mori, H, Wakabayashi, K, Eds, pp 162-166, 2008.
35. Ferrara N. Vascular endothelial growth factor. In: Encyclopedic Reference of Molecular Pharmacology. Springer, 2008.
36. Ferrara, N. Vascular endothelial growth factor: basic biology and clinical applications. In: From local invasion to metastatic cancer. Leong, S. Ed. Humana Press, pp 11-29, 2009.
37. Ferrara, N, Crawford, Y. Pathophysiology of vascular endothelial growth factor and other angiogenic molecules. In: Retinal Pharmacotherapy. Nguyen, Q-D, Rodrigues, EB, Farah, ME, Mieler, WF. Eds. Saunders, pp 230-235, 2010.
38. Ferrara, N,. Role of myeloid cells in tumor angiogenesis. In: Twenty years of G-CSF: clinical and non clinical discoveries. Molineaux, AW and Arvedson, T, Eds. Springer, pp 423-433, 2012.
39. Ferrara, N. Vascular endothelial growth factor. In: Brenner's Online Encyclopedia of Genetics. Maloy, S, Hughes, K, Eds. 2nd Edition. Elsevier. 2013.
40. Zhuang, G, Ferrara, N. The VEGF Receptor Family. In: Receptor Tyrosine Kinases:

- Family and Subfamilies. Wheeler, L, Yarden, Y, Eds. Humana Press, pp 821-841, 2015.
41. Ferrara, N. Role of the VEGF signaling pathway in tumor angiogenesis. In: Angiogenesis: A key target for cancer therapy. Marme', D. Ed. pp 211-226, Springer 2019.
 42. Mori, T, Kumar, N RN, Zhou, Wenjing, Ferrara N. The Complex Interplay Between VEGF and Cytokines in the Regulation of Pathological Angiogenesis. In Mantovani, A, Palmieri, A Eds. Encyclopedia of Immunobiology, 2nd Edition. <https://www.sciencedirect.com/science/article/abs/pii/B978012824465400226X?via%3Dihub>

Patents

1. Ferrara, N, Leung, DW. Production of vascular endothelial growth factor and DNA encoding same. US Patent 5332671. July 26, 1994.
2. Ferrara, N, Leung, DW. Production of vascular endothelial growth factor and DNA encoding same. European Patent 0471754. July 31, 1996.
3. Ferrara, N, King, K, Luis, E, Mather, J, Paoni, N. Use of leukemia inhibitory factor and endothelin antagonists. US Patent 5573762. Nov. 12, 1996.
4. Ferrara, N, Gospodarowicz, D, Plouet, J. Endothelial cell growth factor. Methods of isolation and expression. European Patent 0464155. May 7, 1997.
5. Ferrara, N, King, K, Luis, E, Mather, J, Paoni, N. Methods of treating heart failure using leukemia inhibitory factor antagonists optionally with endothelin antagonists. US Patent 5837241. Nov. 17, 1998.
6. Davis-Smyth, T, Chen, H, Presta, L, Ferrara, N. Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production. US Patent 5952199. Sept. 14, 1999.
7. Keyt, BA, Nguyen, FH, Ferrara, N. Nucleic acids encoding variants of vascular endothelial cell growth factor. US Patent 6020473. Feb. 1, 2000.
8. Keyt, BA, Nguyen, FH, Ferrara, N, Cunningham, B Wells, JA, Li, B. Variants of vascular endothelial cell growth , theirs uses and processes for their production. US Patent 6057428. May 2, 2000.
9. Fong, S, Ferrara, N, Goddard, A, Godowski, PJ, Gurney, A, Hillan, KH, Williams, PM. Nucleic acids encoding nl-3. US Patent 6074873. June 13, 2000.

10. Davis-Smyth, T, Chen, H, Presta, L, Ferrara, N. Receptors as novel inhibitors of vascular endothelial growth factor activity, and processes for their production. US Patent 6100071. Aug. 8, 2000.
11. Ferrara, N, Isner, JM, Schwall, RH. Angiogenesis using hepatocyte growth factor. US Patent 6133231. Oct. 17, 2000.
12. Ferrara, N, King, K, Luis, E, Mather, J, Paoni, N. Use of leukemia inhibitory factors and endothelin antagonists. US Patent 6156733. Dec. 5, 2000.
13. Fong, S, Ferrara, N, Goddard, A, Godowski, PJ, Gurney, A, Hillan, K, Williams, PM. Tie receptor tyrosine kinase ligand homologues. US Patent 6348351. Feb. 19, 2002.
14. Ferrara, N, Kim KJ. Use of anti-VEGF antibodies for the treatment of cancer. European Patent 0666868. April 3, 2002.
15. Ferrara, N, Kuo, S. Polypeptides having homology to vascular endothelial growth factor and bone morphogenetic protein 1. US Patent 6391311. May 21, 2002.
16. Davis-Smyth, T, Chen, H, Presta, L, Ferrara, N. Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production. US Patent 6383486. May 7, 2002.
17. Godowski, P, Gurney, Hillan, K, A, Botstein, D, Goddard, A, Roy, M, Ferrara, N, Tumas, D, Schwall, R. NL4 TIE ligand homologue nucleic acid. US Patent 6413770. July 2, 2002.
18. Ferrara, N, Kuo, S. Polypeptides homologous to VEGF and BMP-1. US Patent 6455283. Sept, 24, 2002.
19. Peyman, A, Knolle, J, Breipohl, G, Scheunemann, K-H, Gadek, T, McDowell, R, Bodary, S, Ferrara, N, Cuthbertson, A. Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists. European Patent 1042301. Nov. 20, 2002.
20. Peyman, A, Knolle, J, Breipohl, G, Scheunemann, K-H, Gadek, T, McDowell, R, Bodary, S, Ferrara, N, Cuthbertson, A. Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists. US Patent 6492356. Dec. 10, 2002.
21. Ferrara, N, King, K, Luis, E, Mather, J, Paoni, N. Use of leukemia inhibitory factors and endothelin antagonists. European Patent 830143. March 5, 2003.
22. Godowski, PJ, Gurney, A, Hillan, K, Botstein, D, Goddard, A, Roy, M, Ferrara, N, Tumas, D, Schwall, R. Tie 2 ligand homologues. US Patent 6551822. April 22, 2003.
23. Ferrara, N, Kuo, S. Polypeptides homologues to VEGF and BMP-1. US Patent 6620784. Sept. 16, 2003.
24. Ashkenazi, A, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Filvaroff, E, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Klijavin, I, Mather, J, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Williams, M,

- Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 6635468. Oct. 21, 2003.
25. Ferrara, N, King, K, Luis, E, Mather, J, Paoni, N. Use of leukemia inhibitory factors and endothelin antagonists. US Patent 6653287. Nov. 25, 2003.
 26. Ashkenazi, A, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Filvaroff, E, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Klijavin, I, Mather, J, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 6664376. Dec. 16, 2003.
 27. Keyt, BA, Nguyen, HF, Ferrara, N. Variants of vascular endothelial growth factor having antagonistic properties. European Patent 0931092. January 17, 2004.
 28. Ashkenazi, A, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Filvaroff, E, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Klijavin, I, Mather, J, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 6723535. April 20, 2004.
 29. Keyt, BA, Nguyen, FH, Ferrara, N. Variants of vascular endothelial cell growth factor, nucleic acids encoding the same and host cells comprising their nucleic acids. US Patent 6750044. June 15, 2004.
 30. Ferrara, N, Kim KJ. Vascular endothelial cell growth factor antagonists. European Patent 0817648. Dec. 12, 2004.
 31. Davis-Smyth, T, Chen, H, Presta, L, Ferrara, N. Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production. US Patent 6897294. May 24, 2005.
 32. Ferrara, N, Gospodarowicz, D, Plouet, J. Endothelial cell growth factor. Methods of isolation and expression. US Patent 6899882. May 31, 2005.
 33. Botstein, D, Desnoyers, L, Ferrara, N. Secreted polypeptide and nucleic acids encoding it. European Patent 1283215. July 27, 2005.
 34. Van Bruggen, N, Ferrara, N. Vascular endothelial cell growth factor antagonists and uses thereof. European Patent 1140173. August 3, 2005.
 35. Ferrara, N, Gao, W-Q, Goddard, A, Gurney, A, Watanabe, C, Wood, WI. Secreted and transmembrane polypeptides and nucleic acids encoding the same. US Patent 6930172. August 16, 2005.
 36. Ferrara, N, Gao, W-Q, Goddard, A, Gurney, A, Watanabe, C, Wood, WI. Secreted and transmembrane polypeptides and nucleic acids encoding the same. US Patent 6965015. Nov. 11, 2005.

37. Ferrara, N. Gao, W-Q, Goddard, A, Gurney, A, Watanabe, C, Wood, WI. Secreted and transmembrane polypeptides and nucleic acids encoding the same. US Patent 6969758. Nov. 29, 2005.
38. Ashkenazi, A, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Filvaroff, E, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Kljavin, I, Mather, J, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Williams, M, Wood, W. Nucleic acid encoding PRO211 polypeptides. US Patent 6974689. Dec. 13, 2005.
39. Keyt, BA, Nguyen, FH, Ferrara, N. Variants of vascular endothelial cell growth factor. US Patent 7005505, Feb. 28, 2006.
40. Baker, K, Botstein, D, Eaton, D, Ferrara, n, Filvaroff, e, Gerritsen, ME, Goddard, a, Godowski, P, Grimaldi, JC, Gurney, A, Hillan KJ, Kljavin, I, Napier, MA, Roy, M, Tumas, D, Wood, WI. Nucleic acids encoding secreted polypeptides that stimulate release of proteoglycans from cartilage. US Patent 7018837. March 3, 2006.
41. Baker, K, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Watanebe, C, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 7026448. April 11, 2006.
42. Baker, K, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Watanebe, C, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 7026449. April 11, 2006.
43. Baker, K, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Pan, J, Paoni, N, Roy, M, Smith, V, Stewart, T, Tumas, D, Watanebe, C, Williams, M, Wood, W. Pro1340 nucleic acids. US Patent 7033786. April 25, 2006.
44. Baker, K, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Watanebe, C, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 7041805. May 9, 2006.
45. Ferrara, N, LeCouter, J. Bv8 nucleic acids and polypeptides with mitogenic activity. US Patent 7060278. June 13, 2006.
46. Baker, K, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Watanebe, C, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 7070955. July 4, 2006.

47. Baker, K, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Watanabe, C, Williams, M, Wood, W. Secreted and transmembrane polypeptides and nucleic acid encoding the same. US Patent 7074592. July 11, 2006.
48. Ferrara, N, Watanabe, C, Wood, W, Shek, T. EG-VEGF nucleic acids and polypeptides and methods of use. US Patent 726480. Sept. 4, 2007.
49. Ferrara, N, Gerber, HP, Kowalski, J, Pisabarro, MT, Sherman, DE. Composition comprising and method of using angiopoietin-like protein 3 Angptl3. US Patent 7267819. Sept. 11, 2007.
50. Ferrara, K, Kuo, S. Antibodies to polypeptides homologous to VEGF and BMP-1. US Patent 7371377. May 13, 2008.
51. Ferrara, N, Goddard, A, Godowski, PJ, Gurney, AL, Wood, WI. PRO-217 polypeptides. US Patent 7378507. May, 25, 2008.
52. Keyt, BA, Nguyen, FH, Ferrara, N. Variants of vascular endothelial cell growth factor: Their uses and processes for their production. US Patent 7427596. Sept. 23, 2008.
53. Ferrara, N, Watanabe, C, Wood, WI. EG-VEGF nucleic acids and polypeptides and methods of use. US Patent 7446168. Nov. 4, 2008.
54. Goddard, A, Gurney, AL, Godowski, PJ, Wood, WI, Ferrara, N. PRO 211 polypeptides. US Patent 7449551. Nov. 11, 2008.
55. Adams, CW, Ferrara, N, Filvaroff, EH, Mao, W, Presta, LG, Tejada, M. Humanized anti-TGF-beta antibodies. US Patent 7527791. May 5, 2009.
56. Ashkenazi, A, Botstein, D, Desnoyers, L, Eaton, D, Ferrara, N, Filvaroff, E, Fong, S, Gao, W-J, Gerber, HP, Gerritsen, M, Goddard, A, Godowski, P, Grimaldi, C, Gurney, A, Hillan, K, Kljavin, I, Mather, J, Pan, J, Paoni, N, Roy, M, Stewart, T, Tumas, D, Williams, M, Wood, W. Anti-PRO 335 antibodies. US Patent 7557192. July 7, 2009.
57. Ferrara, N, Kuo, S. Polypeptides homologous to VEGF and BMP-1. US Patent 7575879. Aug. 18, 2009.
58. Ferrara, N, LeCouter, J. Compositions with hematopoietic and immune activity. US Patent 7632810. Dec. 15, 2009.
59. Desnoyers, L, Ferrara, N, Goddard, A, Godowski, P, Gurney, A, Hillan, KJ, Wood, WI, Filvaroff, E. PRO214 polypeptides. US Patent 7619062. Nov. 17, 2009.
60. Ferrara, N, Hillan, KJ, LeCouter, J. Compositions for liver growth and liver protection. US Patent 7700571. April 20, 2010.
61. Gerber, HP, Ferrara, N, Liang, XH. Inhibitors of angiopoietin-like 4 protein, combinations and their use. US Patent 7740846. June 22, 2010.
62. Davis-Smyth, T, Chen, HH, Presta, LG, Ferrara, N. Methods for using chimeric vascular endothelial growth factor receptor proteins. US Patent 7771721. August 10, 2010.
63. LeCouter, J, Ferrara, N. BV8 nucleic acids and polypeptides with mitogenic activity. US Patent 7811984. October 10, 2010.
64. Van Bruggen, N, Ferrara, N. Vascular endothelial cell growth factor antagonists and uses

- thereof. US Patent 7998931. Aug. 16, 2011.
65. Adams, CM, Ferrara, N, Filvaroff, E, Mao, W, Presta, LG, Tejada, M. Humanized anti-TGF-beta antibodies. US Patent 8012482. Sept. 6, 2011.
 66. Ferrara, N. Transgenic mice expressing humanized VEGF. US Patent 8110720. Feb. 7, 2012.
 67. Ferrara, N, LeCouter, J. Compositions with hematopoietic and immune activity. US patent 8257702. Sept. 4, 2012.
 68. Davis-Smyth, TL, Chen, HH, Presta, L, Ferrara, N. Methods for using inhibitors of vascular endothelial growth factor. US patent 8268313. Sept. 18, 2012.
 69. Davis-Smyth, TL, Chen, HH, Presta, L, Ferrara, N. Compositions and methods for producing inhibitors of vascular endothelial growth factor. US patent 8268591. Sept. 18, 2012.
 70. Van Bruggen, N, Ferrara, N. Vascular endothelial cell growth factor antagonists and uses thereof. US Patent 8287873. October 16, 2012.
 71. Ferrara, N, Watanabe, C. EG-VEGF nucleic acids and polypeptides and methods of use. US Patent 8557238. October 15, 2013.
 72. Gerber, HP, Ferrara, N, Liang, X-H. Inhibitors of angiopoietin-like 4 protein, combinations, and their use. US patent 8604185. Dec. 10, 2013.
 73. Wu, X, Wu, Y, Yu, L, Ferrara, N, Liang, W-C, Meng, G, Tien, J. Anti-Bv8 antibodies and uses thereof. US patent 8771685. July 8, 2014.
 74. Ferrara, N, Shojaei, F, Wu, X, Zhong, C. Inhibition of angiogenesis. US patent 9284369. March 15, 2016.
 75. Ferrara, N. US patent US11,524,053B2 , Methods and Compositions for Treatment of Angiogenic Disorders Using Anti-VEGF Agents. December 13, 2022.
 76. Ferrara, N, Li, Q, Li, P. Composition and Methods for Promoting Angiogenesis in the Eye. US 2022/0105157 A1, April 7, 2022.